Synthetic Oleanane Triterpenoids: Multifunctional Drugs with a Broad Range of Applications for Prevention and Treatment of Chronic Disease

Karen T. Liby and Michael B. Sporn

Departments of Medicine and Pharmacology, Dartmouth Medical School, Hanover, New Hampshire

Abstract............................................................................... B

I. Introduction ........................................................................... B

II. Inflammation and oxidative stress....................................................... C

III. Naturally occurring pentacyclic triterpenoids............................................. D

IV. Biological activities in vitro ............................................................. E

A. Anti-inflammatory and cytoprotective properties....................................... E

B. Differentiation...................................................................... G

C. Antiproliferative and proapoptotic properties.......................................... H

D. Mechanisms of growth arrest and apoptosis ........................................... I

V. Preclinical biological activities in vivo.................................................... K

A. Neurodegenerative diseases.......................................................... K

B. Diseases of the eye.................................................................. L

C. Diseases of the lung..................................................................... L

D. Cardiovascular and circulatory diseases............................................... M

E. Liver diseases and other diseases of the digestive system......................... M

F. Renal diseases. ........................................................................ N

G. Metabolic disorders ...................................................................... N

H. Inflammatory/autoimmune disorders ................................................. N

I. Other diseases...................................................................... O

J. Cancer............................................................................. O

1. Prevention ...................................................................... O

2. Treatment....................................................................... Q

3. In vivo anticancer mechanisms .................................................... R

VI. Signaling pathways and mechanisms of action............................................ S

A. Kelch-like erythroid cell-derived protein with CNC homology-associated protein 1
   (Keap1) ............................................................................ T

B. Peroxisome proliferator-activated receptor γ (PPARγ) ................................ T

C. Inhibitor of nuclear factor-κB kinase complex (IKK) and the nuclear factor-κB pathway . T

D. Janus tyrosine kinase/signal transducer and activator of transcription (JAK/STAT) ....... U

E. Human epidermal growth factor receptor 2 (HER2)/ErbB2/neu .......................... U

F. Phosphatase and tensin homolog (PTEN) and the phosphatidylinositol 3-kinase/protein
   kinase B (PI3K/Akt) pathway .................................................. U

G. Mammalian target of rapamycin (mTOR) ............................................ V

H. Thiol proteome ..................................................................... V

I. Transforming growth factor-β pathway ................................................... W

J. Other pathways .................................................................... X

K. Summary .......................................................................... X

Address correspondence to: Karen Liby, Departments of Medicine and Pharmacology, Dartmouth Medical School, Remsen 524, HB7650, Hanover, NH 03755. E-mail: karen.liby@dartmouth.edu

This article is available online at http://pharmrev.aspetjournals.org.

http://dx.doi.org/10.1124/pr.111.004846.

A

Copyright 2012 by the American Society for Pharmacology and Experimental Therapeutics.
Abstract—We review the rationale for the use of synthetic oleanane triterpenoids (SOs) for prevention and treatment of disease, as well as extensive biological data on this topic resulting from both cell culture and in vivo studies. Emphasis is placed on understanding mechanisms of action. SOs are nontoxic drugs with an excellent safety profile. Several hundred SOs have now been synthesized and in vitro have been shown to: 1) suppress inflammation and oxidative stress and therefore be cytoprotective, especially at low nanomolar doses, 2) induce differentiation, and 3) block cell proliferation and induce apoptosis at higher micromolar doses. Animal data on the use of SOs in neurodegenerative diseases and in diseases of the eye, lung, cardiovascular system, liver, gastrointestinal tract, and kidney, as well as in cancer and in metabolic and inflammatory/autoimmune disorders, are reviewed. The importance of the cytoprotective Kelch-like erythroid cell-derived protein with CNC homology-associated protein 1/nuclear factor-(erythroid-derived 2)-like antioxidant response element (Keap1/Nrf2/ARE) pathway as a mechanism of action is explained, but interactions with peroxisome proliferator-activated receptor γ (PPARγ), inhibitor of nuclear factor-κB kinase complex (IKK), Janus tyrosine kinase/ signal transducer and activator of transcription (JAK/STAT), human epidermal growth factor receptor 2 (HER2)/ErbB2/neu, phosphatase and tensin homolog (PTEN), the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway, mammalian target of rapamycin (mTOR), and the thioredoxin proteome are also described. In these interactions, Michael addition of SOs to reactive cysteine residues in specific molecular targets triggers biological activity. Ultimately, SOs are multifunctional drugs that regulate the activity of entire networks. Recent progress in the earliest clinical trials with 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) methyl ester (bardoxolone methyl) is also summarized.

I. Introduction

Disease inflicts great pain and suffering. Current understanding of the natural history of the mechanisms and processes that cause most common chronic diseases now offers the possibility to prevent or alleviate much of that pain and suffering. Based on such mechanistic understanding, we can now design new preventive drugs to modify the disease process to make it less aggressive, less malignant, and less virulent, to allow a new approach to preventive medicine. This article will review the pharmacological basis for the use of one such class of preventive drugs, the synthetic pentacyclic oleanane triterpenoids (SOs1), in contemporary medicine. Both the inflammatory process and oxidative stress are at the pathogenetic core of so many chronic diseases (Glass et al., 2010; Grivennikov et al., 2010; Nathan and Ding, 2010), including cardiovascular, diabetic, pulmonary, arthritic, gastrointestinal, hepatic, cancerous, renal, or neurodegenerative diseases, and SOs have uniquely potent and safe ability to control inflammation and oxidative stress in almost every part of the body. Therefore, these agents now have the potential to alter patterns of medical practice to a more preventive orientation. This is indeed critically needed, because increasing costs of treating end-stage illness impose increasingly unsustainable economic burdens on society.

1Abbreviations: AKT/Akt, protein kinase B; ALI, acute lung injury; ALS, amyotrophic lateral sclerosis; AML, acute myeloid leukemia; AMPK, AMP-activated protein kinase; APL, acute promyelocytic leukemia; ARDS, acute respiratory distress syndrome; ARE, antioxidant response element; ATRA, all-trans-retinoic acid; Bax, Bcl-2-associated X protein; BAY 11-7082, 3-(4-methylphenyl)sulfonyl-(2E)-propenitrile; Bcl-2, B-cell lymphoma 2; Bcl-xL, B-cell lymphoma-extra large; BMP, bone morphogenetic protein; BRCA, breast cancer associated gene; CBP, cAMP response element-binding protein; CDDO, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid; CGD, chronic granulomatous disease; CKD, chronic kidney disease; CLL, chronic lymphocytic leukemia; ConA, concanavalin A; COPD, chronic obstructive pulmonary disease; CrmA, cytokine response modifier A; CTL, cytotoxic T lymphocyte; DR, death receptor; DTT, dithiothreitol; EA, ethyl amide; eGFR, estimated glomerular filtration rate; Erk, extracellular signal-regulated kinase; GVHD, graft-versus-host disease; Her2/ErB2/neu, human epidermal growth factor receptor 2; HO-1, heme oxygenase-1; IkBα, inhibitor of nuclear factor-κB; I KK, IkB kinase; IL, interleukin; Im, imidazole; iNOS, inducible nitric-oxide synthase; JAK, Janus kinase; jnk, c-Jun N-terminal kinase; Keap1, Kelch-like erythroid cell-derived 2-like antioxidant response element (Keap1/Nrf2/ARE) pathway as a mechanism of action is explained, but interactions with peroxisome proliferator-activated receptor γ (PPARγ), inhibitor of nuclear factor-κB kinase complex (IKK), Janus tyrosine kinase/signal transducer and activator of transcription (JAK/STAT), human epidermal growth factor receptor 2 (HER2)/ErbB2/neu, phosphatase and tensin homolog (PTEN), the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway, mammalian target of rapamycin (mTOR), and the thioredoxin proteome are also described. In these interactions, Michael addition of SOs to reactive cysteine residues in specific molecular targets triggers biological activity. Ultimately, SOs are multifunctional drugs that regulate the activity of entire networks. Recent progress in the earliest clinical trials with 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) methyl ester (bardoxolone methyl) is also summarized.
In this article, we will first provide a brief historical perspective on the inflammatory process and oxidative stress, as well as the use of natural pentacyclic triterpenoids to control these processes. We will then provide an updated summary (previously reviewed in Liby et al., 2007b; Petronelli et al., 2009a) on the development of SOs, from both the perspectives of synthetic organic chemistry and their molecular and cellular mechanisms of action, for prevention of disease in both experimental animals and in the clinic. Finally, we will discuss issues that need to be addressed for these important new agents to have their optimal use for human benefit.

II. Inflammation and Oxidative Stress

The importance of the inflammatory process for the pathogenesis of human disease has long been recognized, if only because of its readily observable four cardinal signs of pain, swelling, redness, and heat in superficial lesions. The pioneering studies of Virchow, Metchnikoff, and others, more than a century ago, began to focus on the cellular basis of inflammation, and it was Virchow’s genius to include cancer as an inflammatory disease based on his microscopic observations of large numbers of macrophages in malignant tumors (Virchow, 1867). By the early 20th century, Virchow’s perspective was largely ignored because of an increasing new emphasis on the cyogenetic aspects of cancer cells (which still dominates contemporary thinking), but approaches other than genetics have had a profound comeback, and it is now realized that the tumor microenvironment plays a critical role during the process of carcinogenesis (Kessenbrock et al., 2010; Dvorak et al., 2011). Inflammatory cells, such as macrophages, neutrophils, and lymphocytes, are not only important for tumor promotion but also have potent ability to generate molecules that directly damage DNA, such as highly reactive species of oxygen, nitrogen, and chlorine, which are clearly mutagenic (Marnett et al., 2003).

Thus, the old sequential paradigm of “tumor initiation,” “tumor promotion,” and “tumor progression” no longer seems to be adequate for a modern framework; all three processes can occur simultaneously in a person. Likewise, inflammatory cells contribute to the process of angiogenesis, which is another critical component of carcinogenesis. Although we have just described the above phenomena in the context of carcinogenesis, they can be equally relevant to many other chronic diseases, whether they be classic “inflammatory” diseases, such as rheumatoid arthritis or multiple sclerosis, or diseases for which a key role of inflammation has only been more recently recognized, such as atherosclerosis, diabetic nephropathy, or various forms of neurodegeneration in which microglia play an important role. In all of these situations, the opportunity to control the inflammatory process offers an opportunity to control pathogenesis.

It also needs to be realized that the hitherto separate processes of inflammation and oxidative stress are really two sides of the same coin, at least within the context of cells and tissues in vivo. Thus, inflammatory cells make reactive species of oxygen (ROS) and nitrogen, which in turn cause oxidative stress in nearby parenchymal cells, which in turn recruit more inflammatory cells to their microenvironment (Shiao et al., 2011; Balkwill and Mantovani, 2012). Furthermore, the production of mitochondrial reactive oxygen species (Rigoulet et al., 2011) in parenchymal cells in turn drives the production and activation of proinflammatory cytokines, further enhancing this vicious circle. There are many different cytokines and peptide growth factors involved in this scenario, whether they be classic cytokines such as the interleukins (there are now more than 30 molecules so named), the interferons, tumor necrosis factor, or a “growth factor” such as TGF-β, which has profound paracrine effects on almost every type of inflammatory cell as well as autocrine effects on the parenchymal cells that may synthesize it. Thus, there is by now an immense literature on the entire tissue network of inflammation and oxidative stress, further enhanced by the more recent concept of the “inflammmasome” (Schroder and Tschopp, 2010; Schroder et al., 2010).

All of this new information is relevant to the potential use of SOs to prevent chronic human diseases. It is intuitively obvious for conditions such as rheumatoid arthritis or multiple sclerosis, in which there is no question of the importance of inflammatory cells, not only in the original genesis of disease but also in the maintenance of the diseased state. Consequently, there are opportunities in such instances for treatment of existing disease as well as for its prevention. More problematic are those inflammatory diseases in which it may be much more difficult to reverse severe pathologic tissue conditions, especially if irreversible cell death has occurred. The brilliant studies of Russell Ross on the inflammatory pathogenesis of atherosclerosis (Ross, 1999) opened up an entire field of cardiovascular investigation. Research on the mechanisms of atherogenesis then led to the clinical development of statins and antiplatelet agents, with important clinical results. These studies and their ensuing results serve as a model for emphasizing prevention at the earliest possible time during pathogenesis. This approach now needs to be extended to the prevention of the neurodegenerative diseases, in which inflammatory and oxidative stress seem to be so critical.

Central to these considerations is the role of the transcription factor Nrf2 and its inhibitor Keap1 in regulating the homeostatic response of the organism to many types of stresses, whether they are inflammatory, oxidative, electrophilic, or metabolic. Nrf2 controls the expression of a large number of genes that enable a coordinated protective response to stress. The Keap1/Nrf2 module is a prime, albeit not exclusive, target of the SOs, and the nature of the chemical
and physical interactions between SOs and Keap1/Nrf2, and the downstream results of this process, are discussed in detail in this review. The general topic of Keap1/Nrf2 is of major current interest (more than 2000 citations in PubMed from 2006 to 2011) and has been the subject of several excellent reviews (Hayes et al., 2010; Taguchi et al., 2011).

It should also be emphasized that not all beneficial effects of the SOs are necessarily mediated by their anti-inflammatory or antioxidative actions. Thus, in an important review (Sheng and Sun, 2011), the ability of multitargeted triterpenoids to regulate glucose and lipid metabolism have been described. This then results in useful hypoglycemic and hypolipidemic effects that are of potential preventive and therapeutic benefit for diabetes and cardiovascular disease. Nrf2 is known to regulate transcription of many genes involved in lipid metabolism (Shin et al., 2007), but other proteins regulated by the SOs may also play a role in this regard. The importance of the multifunctional aspects of pentacyclic triterpenoids, and the molecular basis of their actions, are emphasized in our discussion in section VI. The SOs are most definitely not “magic bullets,” and they do not fit the single-target paradigm that dominates so much of present-day pharmaceutical research. The single-target paradigm has been unusually unsuccessful in developing new drugs for prevention and treatment of chronic disease, and it is now essential that we move beyond this to a more realistic approach as to how cells, tissues, and organs actually function. We have allowed ourselves to be mesmerized by the “magic” of imatinib (Gleevec), which turns out to be not a single-target drug but a multikinase inhibitor (Hasinoff and Patel, 2010). The media and publicity blitz that attended the great success of the introduction of this important drug in the treatment of chronic myelogenous leukemia has not been particularly helpful in furthering support for research on multifunctional drugs such as triterpenoids, and it is time to realize how critical multifunctionality may be, in terms of both direct drug action and lessening the development of drug resistance. To quote Richard Feynman, “Reality must take precedence over public relations, for nature cannot be fooled.” We turn our attention to the use of new SOs for prevention of disease, after providing a brief introduction to the topic of natural triterpenoids, how they exist in nature, and how they have been used, especially in Asian cultures, for medicinal purposes.

III. Naturally Occurring Pentacyclic Triterpenoids

Pentacyclic triterpenoids are ancient molecules. Triterpenoid hopanoid molecules have been identified in Archaea from prehistoric geological sediments. The fundamental isopentenyl pyrophosphate pathway plays a central role in the biological generation of all triterpenoids, as well as for monoterpenes, sesquiterpenes, diterpenes, and carotenoids, including the retinoids, which are critical metabolites of carotenoids. Although the carotenoids are biosynthesized from isoprenoid geranyl pyrophosphate, farnesyl pyrophosphate, and geranylgeranyl pyrophosphate precursors, the cyclic triterpenoids are biosynthesized from other linear isoprenoid 30-carbon precursors: either squalene (in the case of hopanoids) or oxidosqualene (in the case of most other cyclic triterpenoids) (Phillips et al., 2006). The basic reaction patterns for the biosynthesis of triterpenoids were elucidated more than 50 years ago by Ruzicka and colleagues, and a biogenetic “isoprene rule” was proposed. This then led to classic synthetic work by the groups of Corey, Ireland, Johnson, Stork, Van Tamelen, and others (for review and specific references, see Sheng and Sun, 2011), which further confirmed the structures of many naturally occurring pentacyclic triterpenoids. It is now possible to achieve total chemical synthesis of many naturally occurring triterpenoids, but plants are usually much more practical sources because very high amounts of triterpenoids are found in many plants and are easily extracted. Thus, crystalline ursolic acid (UA) of high purity is easily obtained in 20% yield by methanol extraction of rosemary leaf; the lupane alcohol betulin accounts for up to 20% of the dry weight of the bark from many species of common birch trees; and oleanolic acid (OA) can be easily obtained in high yield from olive pulp remaining after the oil is pressed from the olive fruit, as well as from olive leaves that are usually discarded after the trees are pruned (Jäger et al., 2009). These natural products, cheaply obtainable, can then serve as scaffolds for further modification by the organic chemist to achieve marked enhancement of the biological activity originally present.

There are almost 100 different patterns into which either squalene or oxidosqualene can be folded in nature to generate cyclic triterpenoids. Unique cyclase enzymes catalyze the different folding patterns (Phillips et al., 2006; Siedenburg and Jendrossek, 2011). From the further metabolism of these various skeletons, plants have generated some 20,000 different molecules. Many of them have been used medicinally in Asia for centuries. The classic monograph of Tang and Eisenbrand (1992) on “Chinese Drugs of Plant Origin” has 124 chapters, ranging from Acanthopanax senticosus to Ziziphus jujube. Triterpenoid structures are shown in 40 of those chapters, and anti-inflammatory actions of the constituent triterpenoids are described in 31 of the chapters.

The biological significance and meaning of this great diversity of structures in nature is still not well understood. Many of the triterpenoids, such as oleananes, ursanes, and friedelanes (found in the bark of the cork tree) have antibacterial or antifungal actions that are clearly of direct survival benefit to the plant itself or to its fruit (Tang and Eisenbrand, 1992). Benefits to animals that feed on plants containing triterpenoids are less clear. Many of the plants that biosynthesize triter-
penoids are readily edible by both wild animals and humans, indicating that the natural molecules are relatively nontoxic and can be ingested safely for long periods of time. Thus, the synthetic organic chemist has relatively safe triterpenoid scaffolds, proven to be without harm in both animals and humans for centuries, on which to conduct further semisynthesis. Furthermore, the known anti-inflammatory activity of some of the natural platforms, such as OA or UA, already serves to target further new drug synthesis toward a desired pharmacological goal.

Moreover, the biological diversity of natural structures indicates that there are fundamental differences between different natural triterpenoids with respect to their interactions with protein targets in an animal cell. Thus, OA and UA differ from each other solely by the location of two methyl groups on their E-ring (both at C-20 on oleanolic acid, one at C-19 and one at C-20 on ursolic acid), but they do not have identical activities; such a small difference conveys unique stereospecificity. Likewise, the stereochemistry of the –OH groups on either OA or UA has important physiological implications; the less common 3-α-OH isomers of both OA and UA have distinct biological activities not shared by the more common 3-β-OH isomers. These steric properties of the exocyclic methyl and other R groups on natural triterpenoids are important determinants of both their activity and their safety, particularly the safety of their derivatives, in a pharmacological setting. This is especially true when the organic chemist adds functional groups that convey the property of Michael addition to the basic scaffold, as by inserting one-one functions, and electron-withdrawing groups such as –CN. Ultimately, the steric hindrance conveyed on the new molecule by the exocyclic methyl groups can prevent a new molecule from being a random alkylating agent and allows the new drug to act more selectively at desired molecular targets (Sporn et al., 2007).

It is important to emphasize that the practical development of pentacyclic triterpenoids as useful pharmacological agents, particularly in contemporary American medical practice, will undoubtedly involve further semi-synthetic modification of natural agents. Most of the pentacyclic triterpenoids, as they occur in nature, do not have enough potency to allow them to be used as successful drugs. To demonstrate activity of natural triterpenoid molecules in many cell culture experiments, one usually needs to employ concentrations as high as 20 μM or above, whereas many of the SOs are highly active at nanomolar levels and, in a few assays, even picomolar levels. The practicalities of dosing humans at milligram rather than gram amounts of drug are obvious.

IV. Biological Activities In Vitro

A. Anti-Inflammatory and Cytoprotective Properties

As described above, the importance of inflammation and oxidative stress in the pathogenesis of so many chronic diseases, including cancer, was the original rationale for making a series of SOs. More than 300 derivatives of OA have been made and screened for their ability to inhibit the de novo synthesis of the inflammatory enzyme inducible nitric-oxide synthase (iNOS). The rationale for choosing OA, a summary of the most important chemical modifications, and biochemical insights into the biological activities of the SOs are summarized by Sporn et al. (2011). The most active and useful SO derivatives (shown in Fig. 1) include several modifications at the C17 position of CDDO (2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid); methyl ester (CDDO-Me; bardoxolone methyl), imidazolidole (CDDO-Im), di-CDDO (nitrile at C17 position of CDDO; TP-225) and various amides (methyl amide, CDDO-MA; ethyl amide, CDDO-EA; or trifluoroethyl amide, CDDO-TFEA). All of these compounds are active at low nanomolar concentrations for inhibiting the induction of iNOS in primary macrophages or in RAW264.7 macrophage-like cells stimulated with inflammatory cytokines. The SOs are equally effective at suppressing NO (nitric oxide) secretion if the cells are stimulated with interferon γ, alone or in combination with both TNFα and IL1β, or with lipopolysaccharide (LPS) (Honda et al., 1998; Suh et al., 1999; Place et al., 2003; Liby et al., 2007a,b). The SOs also block production of a variety of inflammatory cytokines and chemokines from immune or tumor cells (Chauhan et al., 2004; Thimmulappa et al., 2006b; Liby et al., 2009; Nichols et al., 2009; Auletta et al., 2010; Liby et al., 2010; Saha et al., 2010; Segal et al., 2010; Hogan et al., 2011), as summarized in Table 1.

A series of microarray studies revealed that the same concentrations of SOs that inhibit iNOS and other inflammatory cytokines also up-regulate a family of cytoprotective genes regulated by the transcription factor Nrf2 (Liby et al., 2005). In its inactive state, Nrf2 is targeted for ubiquitination and proteasomal degradation through its interaction with the Keap1 protein. In response to oxidative or electrophilic stress or after direct interaction of a compound such as a SO with Keap1, Nrf2 dissociates from Keap1. Nrf2 then forms dimers with maf proteins or other members of the Cap’n’Collar/basic leucine zipper family of transcription factors and binds to the antioxidant response element (ARE) on a number of target genes (Giudice et al., 2010; Taguchi et al., 2011). These Nrf2-responsive genes include Quinone reductase 1, γ-Glutamylcysteine synthetase, Thioredoxin, Thioredoxin and glutathione reductase, Glutathione and UDP-glucuronyl transferases, Epoxide hydrolase, Superoxide dismutase, Catalase, and Heme oxygenase 1. The proteins encoded by these genes function as direct antioxidants, metabolize free radicals, conjugate and detoxify natural and xenobiotic electrophiles, promote glutathione homeostasis, regulate the proteasome and molecular chaperones, recognize DNA damage, and inhibit inflammation (Itoh et al., 2010; Slocum and Kensler, 2011). The coordinated up-regulation of
This network of phase 2 responsive genes is able to inactivate the original insult. The SOs are some of the most potent activators of the Nrf2 pathway in vitro (Lapillonne et al., 2003; Dinkova-Kostova et al., 2005; Liby et al., 2005) and in vivo (Liby et al., 2005; Yates et al., 2006, 2007, 2009). As would be predicted by their activation of the Nrf2 pathway, pretreating cells with SOs blocks the production of ROS when challenged with oxidants such as tert-butyl hydroperoxide, but this reduction in ROS is absent in Nrf2(-/-) cells (Liby et al., 2005). The SOs also protect against cell death from photooxidation in retinal pigment epithelial cells treated with UVA radiation (Dinkova-Kostova et al., 2005). It is noteworthy that the ability of triterpenoids to suppress NO production is lost in Nrf2-knockout fibroblasts stimulated with inflammatory cytokines.

Although protection against oxidative stress is a well known function of Nrf2 activation, the anti-inflammatory effects of the Nrf2 pathway were not widely understood, and the SOs were the original compounds used to show that these two pathways are mechanistically linked. The potencies for the induction of NQO1 enzyme activity and the suppression of iNOS are highly correlated over 6 orders of magnitude for 18 different triterpenoids.

![Triterpenoid structures. A, structure of oleanolic acid, the starting material for the synthetic oleanane triterpenoids (SOs), showing important positions and functionalities that have been modified to enhance the potency of the SOs: the C-28 carboxyl group (blue), the double bond at C-12/C-13 (red), and the hydroxyl group at C-3 (red). B, structures of the most useful SOs, the biological activities of which are summarized in the text. The numbering system and ring structure for all of the SOs are the same as for oleanolic acid. In CDDO, the A ring has been activated by formation of an enone function at C-1, C-2, and C-3 (red) and the insertion of a strong electron-withdrawing –CN group at C-2 (blue), which facilitates Michael addition at C-1; the C ring has been activated by the inclusion of another enone function at C-9, C-11, and C-12 (red). The rest of the SOs shown can be considered analogs of CDDO. Additional modification at C-28 (green) has been useful for generating biologically useful molecules with different pharmacokinetic properties. (A and B adapted from Liby KT, Yore MM, and Sporn MB (2007) Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 7:357–369. Copyright © 2007 Nature Publishing Group. Used with permission.) C, the importance of the presence and location of the enone function in both the A and C rings for enhancing potency is shown by the CD (concentration required to double the specific activity) values for the induction of NQO1 enzyme activity; NQO1 is a classic Nrf2 target gene. [Adapted from Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, Williams C, Risingsong R, Honda T, Gribble GW, Sporn MB, and Talalay P (2005) Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA 102:4584–4589. Copyright © National Academies of Science, USA. Used with permission.]
penoids (Dinkova-Kostova et al., 2005). The decreased mRNA expression of the cytokines TNFα and IL-6 and the chemokines MCP1 and Mip2 in neutrophils after treatment with CDDO-Im also requires expression of Nrf2 (Thimmulappa et al., 2006b). Numerous studies have revealed that activation of the Nrf2/ARE pathway suggests that potent activators of this pathway could serve as "multiorgan protectors" (Lee et al., 2005) against a number of diseases in which inflammatory pathway (< 0.01 μM), the SOs also induce differentiation of a variety of primary leukemic blasts or human leukemia cell lines, in addition to neuronal differentiation of PC12 cells, adipocytic differentiation of 3T3L1 fibroblasts, osteoblastic differentiation of Saos-2 osteosarcoma cells, and megakaryocytic differentiation of normal hemopoietic progenitor cells. Additive or synergistic effects are obtained when SOs are combined with the retinoid ATRA, the rexinoid 6-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)nicotinic acid (LG100268), and 1α,25(OH)2 vitamin D3 or related deltanoids. These studies are summarized in Table 2.

### B. Differentiation

At slightly higher concentrations than those required to inhibit inflammation and induce the Nrf2 pathway (< 0.01 μM), the SOs also induce differentiation of a variety of primary leukemic blasts or human leukemia cell lines, in addition to neuronal differentiation of PC12 cells, adipocytic differentiation of 3T3L1 fibroblasts, osteoblastic differentiation of Saos-2 osteosarcoma cells, and megakaryocytic differentiation of normal hemopoietic progenitor cells. Additive or synergistic effects are obtained when SOs are combined with the retinoid ATRA, the rexinoid 6-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)nicotinic acid (LG100268), and 1α,25(OH)2 vitamin D3 or related deltanoids. These studies are summarized in Table 2.

#### Although the mechanisms responsible for induction of cell differentiation by the SOs are not completely understood, several clues have emerged. It is noteworthy that there are differences between SOs, especially during

### TABLE 2

SOs induce cell differentiation in vitro

<table>
<thead>
<tr>
<th>Cells Undergoing Differentiation</th>
<th>Triterpenoid</th>
<th>Combination(s)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>U937, THP-1 ll monocytic leukemia cells; LCDB, NB4 myelocytic leukemia cells</td>
<td>CDDO</td>
<td>Deltanoid ILX23-7553</td>
<td>Suh et al., 1999; Place et al., 2003</td>
</tr>
<tr>
<td>HL-60 granulomonocytic leukemia cells and/or AML primary blasts</td>
<td>CDDO Im</td>
<td>ATRA</td>
<td>Suh et al., 1999; Place et al., 2003</td>
</tr>
<tr>
<td>NB4 and MR2 acute promyelocytic leukemia cells and primary APL cells</td>
<td>CDDO</td>
<td>TGF-β</td>
<td>Suh et al., 1999</td>
</tr>
<tr>
<td>Neuronal differentiation of PC12 pheochromocytoma cells</td>
<td>CDDO</td>
<td>TGF-β superfamily</td>
<td>Suh et al., 1999</td>
</tr>
<tr>
<td>Adipogenic differentiation of 3T3L1 fibroblasts</td>
<td>CDDO</td>
<td>ATRA</td>
<td>Suh et al., 1999; Wang et al., 2000</td>
</tr>
<tr>
<td>Saos-2 osteosarcoma cells</td>
<td>CDDO</td>
<td>None</td>
<td>Petronelli et al., 2011</td>
</tr>
<tr>
<td>Megakaryocytic differentiation of normal hemopoietic progenitor cells and HEL and TF1 human erythroleukemic cell lines</td>
<td>CDDO</td>
<td>None</td>
<td>Suh et al., 2012</td>
</tr>
</tbody>
</table>

### TABLE 1

SOs inhibit the production of inflammatory mediators in various cells

<table>
<thead>
<tr>
<th>Triterpenoid</th>
<th>Reduced Inflammatory Mediators</th>
<th>Cell Type</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDDO</td>
<td>NO, iNOS, COX-2</td>
<td>Peritoneal macrophages, human colon myofibroblasts</td>
<td>Honda et al., 1998; Suh et al., 1999</td>
</tr>
<tr>
<td>CDDO</td>
<td>MMP-1, MMP-13</td>
<td>Chondrosarcoma cells, human chondrocytes</td>
<td>Elliott et al., 2003; Mix et al., 2001</td>
</tr>
<tr>
<td>CDDO-Im</td>
<td>IL-6</td>
<td>Multiple myeloma cells</td>
<td>Chauhan et al., 2004</td>
</tr>
<tr>
<td>CDDO-Me</td>
<td>VEGF, COX-2, MMP-9</td>
<td>Human leukemia cells</td>
<td>Shishodia et al., 2006</td>
</tr>
<tr>
<td>CDDO-Im</td>
<td>TNFα, IL-6, Mip1, Mip2</td>
<td>Neutrophils</td>
<td>Thimmulappa et al., 2006b</td>
</tr>
<tr>
<td>CDDO</td>
<td>IL-6, TNFα</td>
<td>Human PBMCs</td>
<td>Thimmulappa et al., 2007</td>
</tr>
<tr>
<td>CDDO-Im</td>
<td>Serum IFNγ, TNFα</td>
<td>N.A.</td>
<td>Osburn et al., 2008</td>
</tr>
<tr>
<td>CDDO-Me</td>
<td>TNFα, IL-1β, IL-6, IL-10, MIP-2, KC</td>
<td>Microglia and peritoneal macrophages</td>
<td>Tran et al., 2008</td>
</tr>
<tr>
<td>CDDO</td>
<td>IL-8, IL-1β, IL-6, TNFα, MIP2, KC</td>
<td>Primary airway epithelia and bronchoalveolar lavage</td>
<td>Nichols et al., 2009</td>
</tr>
<tr>
<td>CDDO-Im</td>
<td>TNFα, IL-17, GCSF, IL-23, LIX</td>
<td>Bronchoalveolar lavage fluid</td>
<td>Segal et al., 2010</td>
</tr>
<tr>
<td>CDDO</td>
<td>TNFα</td>
<td>Pancreatic cancer cells</td>
<td>Liby et al., 2010</td>
</tr>
<tr>
<td>CDDO-Me</td>
<td>IL-6, IL-12p70, IFN-γ, IL-6, IL-17, IL-23</td>
<td>Splenocytes</td>
<td>Auletta et al., 2010</td>
</tr>
<tr>
<td>CDDO-Im</td>
<td>IL-6, IL-10, TGF-β</td>
<td>Human lung fibroblasts</td>
<td>Hogan et al., 2011</td>
</tr>
<tr>
<td>CDDO-Me</td>
<td>IL-6, IL-17, IFNα, TNFα, GM-CSF</td>
<td>Primary orthotopic breast tumors</td>
<td>Liao et al., 2011</td>
</tr>
<tr>
<td>CDDO-Me</td>
<td>CXCL12, CCL2, MMP-9</td>
<td>Blood lymphocytes from mice with EAE</td>
<td>Pareek et al., 2011</td>
</tr>
<tr>
<td>CDDO-Im</td>
<td>IL-6, IL-10, IFNα, TNFα, GM-CSF</td>
<td>Primary tumor cells from PyMT mice</td>
<td>Tran et al., 2012</td>
</tr>
</tbody>
</table>

adipogenesis. CDDO releases nuclear receptor corepressor 1 and recruits the coactivator CBP, a cAMP response element-binding binding protein, from the PPARγ receptor to induce differentiation of 3T3L1 cells to adipocytes, but CDDO-Me does not regulate these transcriptional regulators or induce adipogenic differentiation. It is noteworthy that CDDO induces adipocyte differentiation when used at doses between 10 and 100 nM but inhibits differentiation induced by the PPARγ agonist rosiglitazone when used at 1 μM (Wang et al., 2000). Treatment with 25 nM CDDO-Im inhibits the differentiation of MEFs into adipocytes stimulated with rosiglitazone, but this inhibition is absent in MEFs from Nrf2(−/−) mice (Shin et al., 2007). As previously suggested, CDDO, but not CDDO-Me, binds to PPARγ (Wang et al., 2000), and the enhanced differentiation of APL cells with the combination of CDDO and ATRA follows enhanced transcription of the PPARγ and RARβ2 genes and acetylation of histone H3 in RARβ2. Both the N-(4-aminopyridyl-2-chloro-5-nitrobenzamide (T007) PPARγ antagonist and PPARγ small interfering RNA partially reduce APL differentiation (Tabe et al., 2007). CDDO also activates the PPARγ receptor in leukemia cells by recruiting the vitamin D-interacting protein 205 (DRIP205) coactivator. The induction of differentiation by CDDO is enhanced in HL-60 cells overexpressing DRIP205, but the PPARγ antagonist T007 blocks differentiation when these cells are treated with CDDO (Tsao et al., 2010).

In osteosarcoma cells overexpressing the extrinsic caspase-8 inhibitor cytokine response modifier A (CrmA), but not in cells overexpressing Bcl-XL, CDDO fails to induce alkaline phosphatase activity, suggesting that induction of differentiation in osteoblasts by CDDO requires caspase-8 (Ito et al., 2001). CDDO-Im enhances ATRA-induced differentiation of APL cells and down-regulates expression of the PML/RARα fusion protein, most likely through activation of caspases, because the decreased PML/RARα expression is blocked when the pan-caspase inhibitor N-benzyloxy carbonyl-Val-Ala-Asp-fluoromethyl ketone is included (Ikeda et al., 2005). In HL-60 cells, CDDO-Im rapidly phosphorylates Erk1/2, enhances Smad phosphorylation, and up-regulates expression of CCAAT/enhancer-binding protein β (CEBPB). The Erk1 inhibitor 2′-amino-3′-methoxy flavone (PD98059), a neutralizing TGF-β antibody, and the BMP antagonist noggin partially reduce the HL-60 differentiation of these cells by CDDO-Im (Ji et al., 2006). Differentiation of both granulocytes and monocytes requires the CCAAT/enhancer-binding protein α (CEBPA) transcription factor, and inappropriate expression or function of this transcription factor occurs in many cases of AML. CDDO initiates transcription of the p42 isoform of CCAAT/enhancer-binding protein α and thus improves the ratio of the active p42 isoform to the inactive p30 isoform in HL-60 cells and in AML blasts (Koschmieder et al., 2007). Low doses (10–50 nM) of CDDO-Im also induce differentiation of normal erythroid cells and megakaryocytes by altering expression of key transcription factors. CDDO-Im enhances phosphorylation of Erk1/2, decreases GATA-1 expression, and enhances GATA-2 and Friend of GATA-1 (FOG-1) expression in these cells. Although the differentiation of megakaryocytes by CDDO-Im could be a beneficial therapy for improving platelet counts, even low doses of CDDO-Im may inhibit the proliferation and survival of erythroid cells (Petronelli et al., 2011). These results suggest that the effects of this drug on normal hematopoiesis should be monitored if used for cancer treatment (Sardina et al., 2011), but these adverse effects have not been observed in clinical trials with the SOs.

C. Antiproliferative and Proapoptotic Properties

As summarized in Table 3, the SOs inhibit proliferation and induce apoptosis in vitro in a wide variety of human and rodent cancer cells, including all of the common forms of epithelial cancers as well as myelomas, leukemias, and sarcomas. CDDO-Me and CDDO-Im are equipotent and approximately 1 log more active than CDDO itself. Effective concentrations for suppressing cell growth in vitro are approximately 0.1 to 1 μM for the most active analogs, with slightly higher concentrations (0.5–5 μM) required to induce apoptosis in vitro. Although even higher concentrations of SOs have been reported to induce apoptosis, these concentrations are not physiologically relevant, even for cell culture studies, because there is no evidence that these very high concentrations can be achieved in tissue in vivo. The ability of the SOs to inhibit proliferation and induce apoptosis is usually independent of the p53, PPARγ, or multidrug resistance status of the cell (Kim et al., 2002; Konopleva et al., 2002; Lapillonne et al., 2003; Place et al., 2003; Melichar et al., 2004; Cinthlarlapalli et al., 2005; Ray et al., 2006). It is noteworthy that several studies have reported that concentrations of SOs that kill malignant cells have no effect on normal lymphocytes harvested from the same cancer patient or from healthy volunteers (Suh et al., 2003b; Chauhan et al., 2004; Ikeda et al., 2004; Kress et al., 2007).

Combining SOs with a variety of other drugs enhances the selective apoptosis of cancer cells compared with either agent alone: CDDO-Me and either ATRA or LG100268 in AML (Konopleva et al., 2002); CDDO + ATRA in APL (Tabe et al., 2007); CDDO-Im + arsenic trioxide in APL (Ikeda et al., 2005); CDDO + bexarotene in mycosis fungoides and Sézary syndrome cells (Zhang et al., 2004); CDDO-Im and bortezomib in multiple myeloma cells (Chauhan et al., 2004); CDDO and inhibitors of the NF-κB pathway [SN50, 3-[4-methylphenyl]sulfon-yl]-(2E)-propenenitrile (BAY11-7082), and helalinen in B-cell lymphoma (Ray et al., 2006); CDDO-Im and the fatty acid synthase inhibitor cerulenin in liposarcoma cells (Hughes et al., 2008); and various SOs + TNF-related apoptosis-inducing ligand (TRAIL) or TRAIL receptor antibodies in AML (Suh et al., 2003b; Riccioni et...
The SOs affect multiple cell cycle proteins to inhibit cell proliferation. Although the SOs can bind to and transactivate the PPARγ receptor (Wang et al., 2000), thus decreasing levels of cyclin D1 (Lapillonne et al., 2003; Konopleva et al., 2006) or inducing caveolin-1 (Chintharlapalli et al., 2005; Konopleva et al., 2006), the SOs can also block cell proliferation by PPARγ-independent mechanisms (Place et al., 2003; Melichar et al., 2004; Zhang et al., 2004; Suh et al., 1999, 2003b; Ito et al., 2000; Konopleva et al., 2002, 2004, 2005; Stadheim et al., 2002; Ikeda et al., 2003, 2005; Place et al., 2003; Inoue et al., 2004; Zhang et al., 2004; Han et al., 2006; Ray et al., 2006; Samudio et al., 2006, 2008; Shishodia et al., 2006; Brooks et al., 2007; Koschmieder et al., 2007; Kress et al., 2007; Tabi et al., 2007, 2010; Elawa et al., 2008; Riccioni et al., 2008; Ahmad et al., 2010; Bernstein et al., 2012).

**D. Mechanisms of Growth Arrest and Apoptosis**

The SOs affect multiple cell cycle proteins to inhibit cell proliferation. Although the SOs can bind to and transactivate the PPARγ receptor (Wang et al., 2000), thus decreasing levels of cyclin D1 (Lapillonne et al., 2003; Konopleva et al., 2006) or inducing caveolin-1 (Chintharlapalli et al., 2005; Konopleva et al., 2006), the SOs can also block cell proliferation by PPARγ-independent mechanisms (Place et al., 2003; Melichar et al., 2004; Zhang et al., 2004; Suh et al., 1999; Lapillonne et al., 2003; Place et al., 2003; Honda et al., 2004; Hyer et al., 2005; Konopleva et al., 2006; Ling et al., 2007; Liby et al., 2008b; Kim et al., 2011).

**TABLE 3**

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>Triterpenoid</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>B and T cell leukemias (AML, APL, CLL, CML, Sézary syndrome), lymphomas/ mycosis fungoides and plasmacytomas</td>
<td>CDDO</td>
<td>Suh et al., 1999, 2003b; Ito et al., 2000; Konopleva et al., 2002, 2004, 2005; Stadheim et al., 2002; Ikeda et al., 2003, 2005; Place et al., 2003; Inoue et al., 2004; Zhang et al., 2004; Han et al., 2006; Ray et al., 2006; Samudio et al., 2006, 2008; Shishodia et al., 2006; Brooks et al., 2007; Koschmieder et al., 2007; Kress et al., 2007; Tabi et al., 2007, 2010; Elawa et al., 2008; Riccioni et al., 2008; Ahmad et al., 2010; Bernstein et al., 2012.</td>
</tr>
<tr>
<td>ER-positive and -negative breast cancer</td>
<td>CDDO</td>
<td>Suh et al., 1999; Lapillonne et al., 2003; Place et al., 2003; Honda et al., 2004; Hyer et al., 2005; Konopleva et al., 2006; Ling et al., 2007; Liby et al., 2008b; Kim et al., 2011.</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>CDDO</td>
<td>Suh et al., 1999; Melichar et al., 2004; Duan et al., 2009; Petronelli et al., 2009b; Gao et al., 2011b.</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>CDDO</td>
<td>Deeb et al., 2007, 2008, 2009, 2010b; Hyer et al., 2008; Vene et al., 2008.</td>
</tr>
<tr>
<td>NSCLC</td>
<td>CDDO</td>
<td>Kim et al., 2002; Zou et al., 2004, 2007, 2008; Liby et al., 2006, 2007a, 2009; Yue et al., 2006.</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>CDDO</td>
<td>Suh et al., 1999; Samudio et al., 2005; Deeb et al., 2010a; Jutooru et al., 2010; Liby et al., 2010.</td>
</tr>
<tr>
<td>Colon cancer</td>
<td>CDDO</td>
<td>Chintharlapalli et al., 2005; Gao et al., 2010, 2011a; Townson et al., 2011.</td>
</tr>
<tr>
<td>Osteosarcoma, chondrosarcoma, liposarcoma, Ewing’s sarcoma, chordoma</td>
<td>CDDO</td>
<td>Ito et al., 2001; Alabran et al., 2008; Hughes et al., 2008; Olsen et al., 2010; Ryu et al., 2010a, b; Yang et al., 2010.</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>CDDO</td>
<td>Chauhan et al., 2004; Ikeda et al., 2004; Liby et al., 2006.</td>
</tr>
<tr>
<td>Melanoma and other skin cancer cells</td>
<td>CDDO</td>
<td>Suh et al., 1999; Hail et al., 2004; Townson et al., 2011.</td>
</tr>
<tr>
<td>Glioblastoma and neuroblastoma</td>
<td>CDDO</td>
<td>Gao et al., 2007; Alabran et al., 2008.</td>
</tr>
</tbody>
</table>

CML, chronic myelogenous leukemia; NSCLC, non–small-cell lung carcinoma.

There are some apparent discrepancies in the literature regarding how the SOs induce apoptosis, but these differences are understandable when the specific triterpenoid used and cell type studied are considered. In contrast to many of the other known biological properties of the triterpenoids, apoptosis seems to be induced through different pathways by different SOs (Liby et al., 2007b; Petronelli et al., 2009a). As reported by several different investigators in some of the earliest studies on SOs, CDDO and CDDO-Im activate extrinsic, death receptor-mediated apoptosis (Ito et al., 2000; Ito et al., 2001; Stadheim et al., 2002; Ikeda et al., 2004), whereas CDDO-Me induces apoptosis through the intrinsic, mitochondrial-dependent pathway (Kim et al., 2002; Konopleva et al., 2002; Samudio et al., 2006). The extrinsic apoptotic pathway is activated by members of the TNF family by recruitment of caspase-8 into the death receptor complex. Bel-2 family members regulate the intrinsic...
mitochondrial pathway; overexpression of Bcl-2 or Bcl-XL blocks the release of cytochrome c from the mitochondria and prohibits apoptosis, whereas increasing the concentration of Bax promotes apoptosis. Defects in the intrinsic pathway are frequently found in chemoresistant leukemias.

In U937 cells overexpressing Bcl-XL, an inhibitor of the intrinsic apoptotic pathway, no loss of transmembrane potential is observed in cells treated with CDDO-Me, but the transmembrane potential is reduced in cells treated with CDDO-Im. Conversely, overexpression of CrmA, an inhibitor of the extrinsic apoptotic pathway, blocks the loss of transmembrane potential induced by CDDO-Im but not by CDDO-Me. The ability of CDDO-Im to induce apoptosis is eliminated by overexpression of CrmA, whereas overexpression of Bcl-XL prevents apoptosis in cells treated with CDDO-Me (Ikeda et al., 2003). CDDO also activates the extrinsic apoptotic pathway in myeloid leukemia and osteosarcoma cells (Ito et al., 2000; Ito et al., 2001; Stadheim et al., 2002).

Although CDDO does induce the release of cytochrome c from the mitochondria, its release follows activation of caspase-8, the subsequent activation of caspase-3, and the capase-8-dependent cleavage of Bid. Overexpression of CrmA blocks the induction of apoptosis by CDDO, whereas Bcl-XL only partially reduces caspase activation and apoptosis (Ito et al., 2000; Ito et al., 2001). As further evidence supporting the importance of the extrinsic pathway, both CDDO and CDDO-Im increase the expression of death receptors (DR) 4 and 5, cell surface receptors for TRAIL, and decrease expression of the antiapoptotic protein FLICE-like inhibitory protein (c-FLIP) (Hyer et al., 2005). CDDO-Me does not affect expression of DR 4 and 5, and knockdown of these DR receptors with small interfering RNA abrogates apoptosis induced by CDDO and CDDO-Im, but not by CDDO-Me, in prostate cancer cells (Hyer et al., 2008). AML blasts expressing low levels of caspase-8 and FADD and high levels of Bcl-XL are also resistant to apoptosis when treated with CDDO-Im (Riccioni et al., 2008).

In contrast, CDDO-Me induces apoptosis in AML cells by increasing levels of the proapoptotic Bax protein, a member of the Bcl-2 family, and inducing caspase-3 cleavage (Konopleva et al., 2002). In lung cancer cells, CDDO-Me causes cytochrome c release from the mitochondria and activation of procaspase-3; the caspase-3 inhibitor N-benzzyloxy carbonyl-Asp-Glu-Val-Asp-fluoromethyl ketone blocks the induction of apoptosis by CDDO-Me (Kim et al., 2002). CDDO-Me also may directly permeabilize the inner mitochondrial membrane, which would deplete mitochondrial glutathione and inhibit electron transport required for respiration (Samudio et al., 2006). Despite the abundance of data suggesting that different SOs signal through separate apoptotic pathways, some exceptions have been reported. In some cells, CDDO-Me can induce apoptosis by the extrinsic pathway by rapidly down-regulating expression of FLICE-like inhibitory protein (FLIP), an endogenous antagonist of caspase-8 (Suh et al., 2003b; Zou et al., 2007), or by activating jnk and C/EBP homologous protein transcription factor (CHOP), thus inducing expression of DR 5 and activation of caspase-8 (Zou et al., 2004; Zou et al., 2008). CDDO has also been reported to induce apoptosis by the intrinsic pathway (Inoue et al., 2004; Konopleva et al., 2004).

The same report describing the induction of different apoptotic pathways by CDDO-Im versus CDDO-Me suggests that CDDO, CDDO-Im, and CDDO-Me all activate the jnk and p38 stress pathways by increasing production of ROS and decreasing glutathione concentrations within the cancer cell (Ikeda et al., 2003). However, the induction of ROS by CDDO-Me in these studies is not as convincing as for CDDO and CDDO-Im. Other studies support the induction of ROS by CDDO and CDDO-Im (Ikeda et al., 2004; Liby et al., 2005; Brookes et al., 2007; Kim et al., 2011), but not by CDDO-Me (Samudio et al., 2006; Yue et al., 2006; Kim et al., 2011). It is noteworthy that the induction of ROS may be selective, because CDDO-Im induces ROS and activates DNA damage signaling pathways in breast cancer cells containing a defective BRCA1 gene but does not induce ROS in nonmalignant breast epithelial cells (Kim et al., 2011). A few exceptions regarding the inability of CDDO-Me to generate ROS have been reported, because high concentrations of this SO may induce apoptosis or autophagy in imatinib-resistant chronic myelogenous leukemia cells by increasing ROS, depleting glutathione and thus disrupting mitochondrial function (Samudio et al., 2008). CDDO-Me also stimulates the production of ROS in pancreatic cancer cells, thereby increasing levels of the ZBTB10 specificity protein repressor and decreasing expression of pro-growth, -survival, and -angiogenesis genes (Jutooru et al., 2010). It is also important to note that the effects of SOs on oxidative stress are bifunctional (Liby et al., 2007b). Higher concentrations (low micromolar) of SOs are required to induce ROS and apoptosis than the low nanomolar concentrations needed to activate the Nrf2/ARE pathway (Liby et al., 2005).

The event that initiates the apoptotic cascade after treatment with an SO has not been identified. Although disruption of the redox balance is one possible mechanism (Ikeda et al., 2003, 2004), ROS induction may be downstream of mitochondrial perturbation instead of an initiating event (Brookes et al., 2007). Other possible signals that may initiate apoptosis by the triterpenoids include altering calcium homeostasis (Hail et al., 2004), activating the jnk or p38 pathways (Ikeda et al., 2003; Zou et al., 2004; Konopleva et al., 2005), depleting mitochondrial glutathione (Samudio et al., 2005), inducing endoplasmic reticulum stress (Zou et al., 2008), inhibiting the NF-κB (Shishodia et al., 2006) and signal transducer and activator of transcription (STAT) pathways (Liby et al., 2006; Petronelli et al., 2009b), or targeting...
the Lon mitochondrial protease (Bernstein et al., 2012). In liposarcoma cells, CDDO-Im may induce apoptosis by targeting fatty acid synthase and thus decreasing the de novo fatty acid synthesis that is required for proliferation and survival of these cells (Hughes et al., 2008). One of the most intriguing hypotheses for the initial step in the apoptotic cascade is that the SOs directly interact with mitochondrial proteins and oxidize thiols, causing high-molecular-weight protein aggregates to form an unregulated permeability transition pore, resulting in the generation of ROS, the release of cytochrome c and apoptosis (Brookes et al., 2007).

V. Preclinical Biological Activities In Vivo

Activation of the Nrf2/ARE pathway by SOs should protect against a number of diseases driven by inflammatory and oxidative stress. Indeed, as summarized below and in Fig. 2, the triterpenoids are effective in a wide variety of preclinical disease models in all of the major organs that have been tested, including the brain, eye, lung, heart, liver, and kidney. The SOs also provide protection against radiation and chemical insults and help regulate the immune system and metabolism. If known, the contribution of Nrf2 activation by the SOs in the various disease models is discussed.

A. Neurodegenerative Diseases

The original biological characterization of CDDO included data indicating that this SO inhibits iNOS formation in primary microglial cultures and protects hippocampal neurons against death induced by β-amyloid (Suh et al., 1999). CDDO-Me also reduces the expression of inflammatory cytokines such as TNFα in microglia without blocking their phagocytic activity, thereby attenuating the production of ROS in dopaminergic neurons and blocking cell death (Tran et al., 2008). Other amide derivatives of CDDO increase activity of the phase 2 cytoprotective enzyme NQO1 and protect against toxicity from hydrogen peroxide in astrocytes and in neurons from rats (Graber et al., 2011). In astrocytes derived from human embryonic stem cells, CDDO-TFEA also activates the Nrf2 pathway, which induces glutamate-cysteine ligase expression and glutathione production and protects against H2O2 toxicity. However, no induction of Nrf2 target genes or neuroprotection is observed in neurons derived from the human embryonic stem cells, suggesting that astrocytes may be necessary for eliminating oxidative stress in the brain (Gupta et al., 2012). Taken together, these in vitro data suggest that if the SOs cross the blood-brain barrier, they might be useful for preventing neurodegenerative diseases.

Although many SOs do not gain access to the brain, several amide derivatives of CDDO can be detected in the brains of mice at concentrations that activate Nrf2-dependent genes in vitro and thus were tested in various animal models of neurodegenerative diseases. CDDO-MA blocks the depletion of striatal dopamine and the loss of tyrosine hydroxylase positive neurons in the 1-methyl-4-phenyl-

![Fig. 2. Activation of the Keap1/Nrf2/ARE/pathway by the SOs is cytoprotective. Nrf2 has been described previously (Lee et al., 2005) as a “multiorgan protector,” because this system can protect against diseases in a number of organs, including the brain, lungs, kidney, heart, liver, and eye. The SOs are among the most potent known inducers of the Nrf2 pathway, and these drugs not only activate Nrf2 in all of these organs but also protect the organs against a variety of diseases driven by inflammatory or oxidative stress. SOs that cross the blood-brain barrier are beneficial in experimental models of neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and ALS. These drugs also reduce damage to the eye from light, uveitis, or ischemia-reperfusion injury, corneal scarring, cardiomyopathy induced by smoking, nephrotoxicity from ischemia-reperfusion injury and cisplatin, hepatotoxicity from aflatoxin, ConA, & acetaminophen, and COPD ALI/ARDS emphysema/asthma fibrosis.](https://pharmrev.aspetjournals.org/article-pdf/10.1124/pr.111.004846/10.1124/pr.111.004846)
1,2,3,6-tetrahydrodipyridine model of Parkinson’s disease and attenuates the lipid peroxidation and α-synuclein accumulation normally caused by treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. In a model of Huntington’s disease, 3-nitropropionic acid causes striatal degeneration, but CDDO-MA reduces the volume of striatal loss by more than 70%. This reduction in neuronal death is accompanied by decreased oxidative damage to proteins, lipids, and DNA in the rats fed CDDO-MA (Yang et al., 2009). CDDO-MA also improves spatial memory and reduces the number and size of amyloid plaques in the hippocampus in a model of Alzheimer’s disease in which mice carry two mutations in the human amyloid precursor protein (Dumont et al., 2009). Compared with CDDO-MA, higher drug levels of CDDO-EA and CDDO-TFEA can be obtained in the brain, and both of these amides prolong survival in transgenic mouse models of Huntington’s disease (Stack et al., 2010) and ALS (Neymotin et al., 2011). Even when treatment is delayed until the onset of motor symptoms in G93A SOD1 mice, the SOs slow progression of ALS and extend the lifespan of these mice (Neymotin et al., 2011). In both of these studies, the SOs up-regulate the transcription of genes regulated by Nrf2, and activation of this pathway with drugs or genetic approaches are beneficial in various animal models of neurodegenerative diseases (Burton et al., 2006; Innamorato et al., 2008; Johnson et al., 2008; Calkins et al., 2009; Escarin and Brouillet, 2010). More recently, CDDO-TFEA has been shown to activate Nrf2-dependent genes, thereby suppressing IL-17 and other Th1 proinflammatory cytokines and attenuating disease progression in experimental autoimmune encephalomyelitis models of multiple sclerosis. Moreover, this triterpenoid also seemed to induce the maturation of oligodendrocytes and enhance the repair of myelin in these studies (Pareek et al., 2011). Further studies have confirmed the importance of Nrf2 for the ability of SO to suppress damage due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (Kaidery et al., 2012).

B. Diseases of the Eye

The SOs also reduce damage to the eye in models of smoking, light damage, uveitis, ischemia/reperfusion, and corneal scarring. Smoking induces oxidative stress in many organs, including the eye, and preliminary studies suggest that CDDO-Im can protect against the inflammatory and oxidative damage caused by smoking in retinal pigment epithelial cells in vivo by activating the Nrf2 cytoprotective pathway (Cano et al., 2010). CDDO-TFEA also induces expression of the Nrf2-target genes NQO1 and GLCL in the retinas of BALB/c mice and protects against retinal degeneration caused by light damage (Pitha-Rowe et al., 2009). Moreover, in a mouse model of uveitis, LPS increases the production of inflammatory cytokines and ROS in both the retina and the iris-ciliary body and also increases the adherence of leukocytes to retinal endothelium. Pretreatment with CDDO-Im increases expression of Nrf2-responsive genes in the retina in wild-type Nrf2 mice and reduces all of the adverse changes induced by LPS, but the protective effects of CDDO-Im against uveitis are lost in Nrf2(-/-) mice (Nagai et al., 2009). Ischemia-reperfusion in the retina also raises levels of superoxide, proinflammatory cytokines, and the infiltration of leukocytes, resulting in neuronal loss and capillary degeneration, and all of these changes are exacerbated in the retinas of Nrf2(-/-) mice. However, CDDO-Me reduces the levels of superoxide and subsequent capillary degeneration after retinal ischemia-reperfusion injury in Nrf2(+/-) mice but not in Nrf2-knockout mice (Wei et al., 2011). Wounds to the cornea, the second most common cause of blindness, initiate the release of cytokines such as TGF-β that induce keratocytes to differentiate into myofibroblasts. CDDO-Me inhibits the differentiation of primary corneal fibroblasts treated with TGF-β into myofibroblasts, as measured by the complete suppression of the in vitro production of α-smooth-muscle actin, collagen, and fibronectin (Kuriyan et al., 2012).

C. Diseases of the Lung

In many lung diseases, a number of stimuli can trigger an inappropriately robust inflammatory response. Genetic inactivation of the Nrf2 pathway exacerbates inflammation, chronic obstructive pulmonary disease (COPD), acute lung injury/acute respiratory distress syndrome (ALI/ARDS), emphysema, asthma, and fibrosis in the airways of Nrf2(-/-) mice (Cho et al., 2002, 2004; Rangasamy et al., 2004, 2005; Goen et al., 2008; Malhotra et al., 2008; Suzuki et al., 2008; Reddy et al., 2009a; Cho and Kleeberger, 2010). The SOs have been shown to be effective in preclinical animal models for all of these diseases, although activation of the Nrf2 pathway is only one of the mechanisms that explain these results, because in many of these studies, treatment with the SOs began after the initiating event.

Smoking is the primary risk factor for COPD, and elevated oxidative stress resulting from reduced activation of the Nrf2 system drives inflammation and apoptosis in the lungs of patients with COPD. Exposure to 6 months of cigarette smoking causes significant enlargement of the alveolar airspace and emphysema in mice, but concomitant treatment with CDDO-Im for the duration of the smoking exposure reduces the alveolar destruction. CDDO-Im also elevates expression of Nrf2 target genes, lowers oxidative stress, and reduces apoptosis in the lungs of the mice exposed to cigarette smoke (Sussan et al., 2009). The up-regulation of Nrf2-regulated genes in the lung by CDDO-Im also protects against hemorrhage, proteinaceous edema, and leukocytic infiltration, all hallmarks of ALI/ARDS, induced by 72 h of hyperoxia. Unexpectedly, the protection against ALI only occurs when CDDO-Im is administered during hypoxic conditions and not when administered before the injury from oxygen (Reddy et al., 2009a). In both the COPD and ALI/ARDS studies, cytoprotection induced by
up-regulation of Nrf2-inducible genes in the lung is observed only in Nrf2(+/+) mice but is lost in Nrf2(−/−) mice.

In lung diseases driven by genetic abnormalities, such as cystic fibrosis and chronic granulomatous disease (CGD), the anti-inflammatory and cytoprotective properties of the SOs are useful for suppressing the disease process. In human airway epithelial cells with a defective Cystic fibrosis transmembrane conductance regulator (CFTR) gene, SOs activate the Nrf2 pathway and inhibit activation of NF-κB. Mutations in this gene prevent normal regulation of chloride and sodium ion transport and cause cystic fibrosis. When mice with a R117H CFTR mutation are pretreated with CDDO and then challenged with LPS or flagellin, the infiltration of neutrophils and the release of the pro-inflammatory cytokines IL-1β, IL-6, macrophage inflammatory protein 2, and keratinocyte-derived cytokine are significantly reduced (Nichols et al., 2009). In CGD, phagocytes do not generate appropriate levels of superoxide or ROS because of inherited defects in NADPH oxidase. Patients with this disease suffer from recurring bacterial and fungal infections that are characterized by inappropriate and excessive inflammation. It is noteworthy that Nrf2 activity is reduced whereas NF-κB activity is activated in PBMCs from patients with CGD. CDDO-Im, however, activates the Nrf2 pathway independently of NADPH oxidase and thereby reduces lung injury caused by zymosan, a pro-inflammatory component of the cell wall in yeast, in a mouse model of CGD. CDDO-Im not only blocks neutrophil infiltration and the release of the pro-inflammatory cytokines TNFα, IL-17, IL-23, lipopolysaccharide-induced CXC chemokine, and granulocyte colony-stimulating factor when given before or after the zymosan challenge but also induces apoptosis in the infiltrating cells (Segal et al., 2010).

The pathophysiology of lung diseases such as idiopathic pulmonary fibrosis, sarcoidosis and even asthma involves fibrotic remodeling and scarring of the lung. Although activation of the Nrf2 pathway can protect against pulmonary fibrosis (Cho et al., 2004), SOs may also block experimental fibrosis through other mechanisms. When wound healing is not properly regulated, TGF-β drives fibroblasts to produce excessive amounts of collagen and fibronectin, which interfere with normal lung function. CDDO prevents the in vitro differentiation of human lung fibroblasts into myofibroblasts induced by TGF-β and the subsequent production of extracellular matrix components such as α-smooth-muscle actin, calponin, fibronectin, and collagen by suppressing acetylation of CBP/p300 (Ferguson et al., 2009a) and phosphorylation of Akt (Kulkarni et al., 2011). Although CDDO up-regulates HO-1 (Ferguson et al., 2009b) and suppresses the production of IL-6, prostaglandin E2, cyclooxygenase-2, and monocyte chemotactic protein-1 and inhibits NF-κB transcriptional activity (Hogan et al., 2011) in human fibroblasts at concentrations similar to those required to inhibit fibrosis, its antiinflammatory effects seem to be independent of HO-1 induction (Ferguson et al., 2009b). These last four studies also found that 15-deoxy-Δ12,14-PGJ2 or PGA1 are active in these assays. However, removal of the electrophilic center in these ligands eliminates protection against fibrosis, suggesting the importance of an α,β-unsaturated carbonyl moiety for bioactivity. This topic will be explored in greater detail when describing molecular targets and mechanisms of the SOs.

D. Cardiovascular and Circulatory Diseases

Activation of the Nrf2 pathway is also useful for maintaining homeostasis in the cardiovascular system. Oxidative stress is a primary contributor to the development and progression of cardiovascular diseases (Li et al., 2009; Koenitzer and Freeman, 2010), but the SOs eliminate the damage of ROS in various models of cardiomyopathy. Dihydro CDDO-TFEA, in which the double bond in the C ring is removed, binds to Keap1, allowing Nrf2 translocation to the nucleus and transcription of Nrf2 target genes in cardiomyocytes in vitro and in vivo. The reduction by this SO in the production of ROS/reactive nitrogen species, which is induced by angiotensin II activation of NADPH oxidase, in these cells is eliminated with knockdown of Nrf2 (Ichikawa et al., 2009). Moreover, by inducing expression of HO-1, CDDO-Im increases the availability of NO and decreases levels of ROS and endothelial NOS in naive or stressed endothelial cells, thus mediating endothelial NOS coupling and vascular homeostasis (Heiss et al., 2009). Although cigarette smoking triggers cardiac dysfunction in the right ventricle that is worse in Nrf2(−/−) mice than in Nrf2(+/+) mice, CDDO-Im prevents the cardiac damage from smoking. Changes to end-systolic pressure, ejection fraction, and isovolumetric relaxation time after 6 months of cigarette smoke are eliminated in mice when CDDO-Im is administered concurrently with cigarette smoke, but the cardioprotective effects of CDDO-Im in this model are mostly absent in Nrf2(−/−) mice (Sussan et al., 2009).

E. Liver Diseases and Other Diseases of the Digestive System

A variety of toxins, chemicals, viruses, and even alcohol can induce inflammation and subsequent cell death in the liver. The resulting activation of the immune system can cause acute liver injury as well as more chronic conditions such as cirrhosis or fibrosis. Induction of phase 2 enzymes regulated by Nrf2 in the liver allows metabolism and elimination of these insults and is protective in both animals and humans (Klaassen and Reisman, 2010), and SOs protect the liver against toxicity from aflatoxin, concanavalin A (ConA), and acetaminophen. By up-regulating the Nrf2/ARE pathway in rats, CDDO-Im significantly blocks the formation of aflatoxin-DNA adducts and reduces the volume of aflatoxin-in-
duced preneoplastic lesions in the liver (Yates et al., 2006). The formation of DNA-aflatoxin adducts is a well recognized risk factor for developing liver cancer, and the chemopreventive agent oltipraz effectively reduces DNA-aflatoxin adducts in humans (Wang et al., 1999). In comparison, CDDO-Im is 30- and 100-fold more potent than 1,2-dithiole-3-thione and oltipraz, respectively, in this assay. During the pathogenesis of hepatitis, ROS released from activated immune cells destroys normal hepatocytes, and this necrosis amplifies the inflammation, forming a destructive feedback loop. The injection of the lectin ConA mimics this process in mice by activating T cells, inflammation, and the death of hepatocytes. Treatment with CDDO-Im before ConA challenge activates the Nrf2 pathway in the liver, which blocks T-cell activation and prevents hepatic necrosis and the accompanying elevated serum ALT levels. In Nrf2-knockout mice, however, CDDO-Im does not reduce the hepatotoxicity that follows treatment with ConA even though it partially reduces levels of early phase proinflammatory cytokines (Osburn et al., 2008). These results suggest that the anti-inflammatory effects of the SOs alone are not sufficient to block liver injury. Pre-treatment with CDDO-Im also lowers hepatotoxicity induced by acetaminophen by activating the Nrf2/ARE pathway, but the protection is lost in Nrf2(-/-) mice (Reisman et al., 2009).

Although the SOs have not been tested in animal models of many other digestive diseases, CDDO can prevent ileitis induced by infection with Toxoplasma gondii in a mouse model of inflammatory bowel disease (Minns et al., 2004). Because activation of the Nrf2 pathway is cytoprotective in the colon (Khor et al., 2006; Theiss et al., 2009) and CDDO-Im induces transcription of Nrf2-target genes such as NQO1 and GCLC in the stomach, small intestine, and colon (Yates et al., 2007), the SOs should also be effective against conditions such as Crohn’s disease, inflammatory bowel disease, and ulcerative colitis. In these diseases, oxidative stress and inflammation can drive pathogenesis (Iborra et al., 2011; Strober and Fuss, 2011).

F. Renal Diseases

The kidneys are involved in the elimination of various chemicals and toxins, so excessive free radicals or oxidative stress can cause renal damage. Deficiency of Nrf2 induces an autoimmune nephritis in aged female mice (Yoh et al., 2001), and activation of the Nrf2 pathway can protect kidneys against ischemia-reperfusion injuries and damage from chemotherapeutic agents (Leonard et al., 2006; Tanaka et al., 2007; Liu et al., 2009). Activation of the Nrf2 pathway may also protect against the oxidative stress implicated as a cause of diabetic nephropathy (Negi et al., 2011). CDDO-Im induces gene transcription of the Nrf2 target genes NQO1 and GCLC in the kidneys, and administration of CDDO-Im 24 to 48 h before treatment with ferric nitritotriacetate prevents the increased serum urea nitrogen and creatinine levels associated with kidney damage (Tanaka et al., 2008). CDDO-Im also protects against cisplatin nephrotoxicity, a dose-limiting side effect frequently associated with the use of cisplatin chemotherapy, because blood urea nitrogen levels and damage to the proximal tubules are reduced in mice treated with CDDO-Im before cisplatin treatment (Aleksunes et al., 2010). As expected, renal damage is worse in Nrf2(-/-) mice challenged with either ferric nitritotriacetate or cisplatin than in wildtype Nrf2(+/+) mice, and the protection against cisplatin toxicity by CDDO-Im is absent in the Nrf2-knockout mice (Aleksunes et al., 2010). By selectively activating transcription of Nrf2 and PPARγ on glomerular endothelia and HO-1 in renal tubules and leukocytes, CDDO-Me improves both renal function and histopathology in a model of mild ischemic acute kidney injury; again, however, only when it is administered before the ischemic injury (Wu et al., 2011b).

G. Metabolic Disorders

Both genetic activation of Nrf2 signaling and pharmacological activation with CDDO-Im induce a number of genes involved in lipid metabolism (Yates et al., 2009), and the SOs are beneficial in preliminary animal studies of obesity and diabetes. Nrf2 can bind to an ARE on the promoter of the aryl hydrocarbon receptor, which then inhibits adipocyte differentiation. By activating Nrf2, CDDO-Im induces Ahr transcription and blocks lipid accumulation in Nrf2(+/+) MEFs but not in Nrf2(-/-) MEFs in vitro (Shin et al., 2007). When given orally to mice, CDDO-Im reduces the weight gain, adipose levels, and lipid accumulation in the liver that accompany a high-fat diet but has no effect on weight gain or energy balance in mice fed a normal diet. The reduction in obesity in the group treated with CDDO-Im is accompanied by increased energy expenditure and down-regulation of pathways regulating fatty acid synthesis in the liver, but these effects are lost in Nrf2-deficient mice (Shin et al., 2009). In mice fed a high-fat diet or in mice with a defective leptin receptor (Leprdb/db), CDDO-Me not only improves glucose tolerance and insulin sensitivity but also lowers levels of free fatty acids and plasma triglycerides. Although CDDO-Me reduces total body fat and suppresses production of the proinflammatory cytokines IL-1, IL-6, and TNFα in mice fed a high-fat diet, the antidiabetic effects of this SO may be mediated by stimulating phosphorylation of LKB1 and AMPK in muscle and liver, as knockdown of AMPK reduces glucose uptake in cells treated with CDDO-Me (Saha et al., 2010).

H. Inflammatory/Autoimmune Disorders

SOs have important activities in macrophages (Honda et al., 1998, 1999, 2000; Tran et al., 2012), human PBMCs and neutrophils (Thimmulappa et al., 2006b; Thimmulappa et al., 2007), B and T lymphocytes (Pedersen et al., 2002; Han et al., 2006; Kress et al., 2007; Sun et al., 2007;
Elsawa et al., 2008; Gao et al., 2008), and myeloid-derived suppressor cells (MDSCs) (Nagaraj et al., 2010). In addition to their direct effects on immune cells themselves, SOs regulate the production and activity of inflammatory cytokines in a variety of diseases. CDDO blocks the induction of matrix metalloproteinase (MMP)-1 and MMP-13 in chondrosarcoma cells and in primary chondrocytes stimulated with IL-1β and TNF-α, and it inhibits cell invasion through collagen (Mix et al., 2001; Elliott et al., 2003; Mix et al., 2004). These MMPs induce the degradation of cartilage, so inhibiting their production may prevent osteoarthritis or rheumatoid arthritis, and Nrf2 deficiency exacerbates arthritis in mice (Maicas et al., 2011; Wruck et al., 2011). It is noteworthy that CDDO also blocks viral replication in macrophages infected with HIV but not through modulation of cytokines (Vázquez et al., 2005).

Inappropriate amplification of the innate immune response can result in sepsis, which can be fatal. LPS from bacterial infections can induce the secretion of proinflammatory cytokines and chemokines from macrophages and neutrophils, and elimination of Nrf2 in vivo exacerbates the lethality from sepsis induced by LPS, cecal ligation, or puncture injury (Thimmulappa et al., 2006a). CDDO-Im also reduces lethality after LPS challenge in mice by activating Nrf2-dependent genes such as HO-1, NQO1, GCLC, and GCLM and by blocking the transcription of TNFα, IL-6, Mcp1, and Mip2 inflammatory mediators, but the protective effect of CDDO-Im is eliminated in Nrf2-knockout mice or in Nrf2-deficient cells (Thimmulappa et al., 2006b). It is noteworthy that activation of these same Nrf2 target genes and suppression of TNFα and IL-6 are detected in human neutrophils and PBMCs, suggesting that SOs might be effective in septic shock and in other disorders characterized by excessive inflammation (Thimmulappa et al., 2007). Indeed, CDDO-Me extends the survival of mice challenged with LPS and decreases circulating levels of IL-6, IL-12, IL-17, IL-23, and interferon γ without altering the numbers or subtypes of immune cells (Auleta et al., 2010).

Because CDDO, CDDO-Me, and CDDO-Im all inhibit T-cell proliferation induced by mitogens or alloantigens in vitro and in vivo (Sun et al., 2007; Gao et al., 2008), they might be useful in graft-versus-host disease (GVHD) or organ transplantation. In a mouse model of GVHD, CDDO prolongs survival and decreases inflammatory-mediated damage in the liver but not in the gastrointestinal tract. It is noteworthy that CDDO does not interfere with engraftment of the donor cells or recovery of myeloid counts (Sun et al., 2007). CDDO-Me is more potent than CDDO, and it inhibits T-cell proliferation, reduces TNFα levels, and delays GVHD without interfering with the treatment for leukemia (Li et al., 2010). In these studies, SOs are administered immediately after transplantation instead of before transplantation. CDDO-Me also can promote the formation and expansion of hematopoietic lineages in both the spleen and bone marrow of mice. This response is dose-dependent, as high concentrations of the drug inhibit proliferation of myeloid cells. Moreover, in mice pretreated with CDDO-Me, myelopoiesis is accelerated after sublethal total-body irradiation or syngeneic bone marrow transplantation (Ames et al., 2012).

1. Other Diseases

Alkylation agents such as sulfur mustard have been used for chemical warfare since World War I and cause debilitating blisters and damage to the skin, cornea, and lungs. CDDO-Im and CDDO-Me can protect human keratinocytes against toxicity from the sulfur mustard analog 2-chloroethyl ethyl sulfide by inducing the synthesis of glutathione, which is depleted by sulfur mustard (Abel et al., 2011). Protection against ionizing radiation is important in the event of a nuclear incident or for treating cancer. Pretreating human colon epithelial cells with CDDO-Me protects them from cell death or transformation induced by radiation (Eskiock et al., 2010). Pre-exposure to CDDO-TFEA also reduces whole organism apoptosis and aberrant development, restores metabolism and renal function, and increases survival of lethally irradiated zebrafish embryos. It is noteworthy that this SO also mitigates damage when administered 1 to 2 h after exposure to radiation (Daroczi et al., 2009).

1. Cancer

1. Prevention. The SOs were originally developed as novel chemopreventive agents (Suh et al., 1999), and more studies have been published on triterpenoids and cancer than any other disease. As summarized in Table 4, the SOs are effective for preventing or treating cancer in a variety of preclinical animal models. Unlike most of the other diseases described previously, there is little evidence that Nrf2 activation is required for much of the anticancer activity of the SOs. Because they are not conventional cytotoxic agents, the SOs are more effective when used to intervene early in the process of carcinogenesis. Aflatoxin ingestion increases the risk of hepatocellular carcinoma in humans, and when administered to rats a week before an aflatoxin challenge, low doses of oral CDDO-Im (1–30 μmol/kg body weight) reduce preneoplastic hepatic foci by 85 to 99% (Yates et al., 2006). The SOs are also active when given after initiation with a UV-damaging or chemical insult. In SKH-1 hairless mice exposed to chronic low-level UVB radiation for 17 weeks and then treated topically with diCDDO (TP-225), skin tumor multiplicity is 50% lower and total tumor burden is 5-fold lower in the mice treated with diCDDO compared with the controls. This SO also increases NQO1 and HO-1 cytoprotective enzyme activity in the skin of these “high risk” hairless mice (Dinkova-Kostova et al., 2008). The SOs are also potent inhibitors of lung carcinogenesis in A/J mice. When fed in the diet, starting 1 week after initiation with vinyl carbamate, CDDO-Me, CDDO-EA, and
TABLE 4
SOs are effective for prevention and treatment of cancer in vivo

<table>
<thead>
<tr>
<th>Triterpenoid</th>
<th>Cancer Model</th>
<th>Treatment or Prevention</th>
<th>Combination</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDDO-Im</td>
<td>Syngeneic L1210 leukemia and B16 melanoma models</td>
<td>Treatment</td>
<td>None</td>
<td>Place et al., 2003</td>
</tr>
<tr>
<td>CDDO</td>
<td>Xenograft of MDA-MB-435 ER-breast cancer cells</td>
<td>Treatment</td>
<td>None</td>
<td>Lapillonne et al., 2003</td>
</tr>
<tr>
<td>CDDO-Im</td>
<td>Xenograft of MDA-MB-468 ER-breast cancer cells</td>
<td>Treatment</td>
<td>TRAIL</td>
<td>Hyer et al., 2005</td>
</tr>
<tr>
<td>CDDO-Im</td>
<td>Liver carcinogenesis induced by aflatoxin in rats</td>
<td>Prevention</td>
<td>None</td>
<td>Yates et al., 2006</td>
</tr>
<tr>
<td>Liposomal</td>
<td>Xenograft of MCF7 ER + breast cancer cells stably overexpressing HER2</td>
<td>Treatment</td>
<td>None</td>
<td>Konopleva et al., 2006</td>
</tr>
<tr>
<td>CDDO</td>
<td>Plasmacytomas in iMyc&lt;sup&gt;++&lt;/sup&gt; transgenic mice</td>
<td>Treatment</td>
<td>None</td>
<td>Han et al., 2006</td>
</tr>
<tr>
<td>CDDO-Me</td>
<td>Lung carcinogenesis induced by vinyl carbamate in A/J mice</td>
<td>Prevention</td>
<td>None</td>
<td>Liby et al., 2007a, 2008a</td>
</tr>
<tr>
<td>CDDO-Ma</td>
<td>4T1/BALB/c model of metastatic breast cancer Treatment None</td>
<td>Ling et al., 2007</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liposomal</td>
<td>TRAF2DIN/Bcl-2 transgenic mouse model of CLL and small B-cell lymphoma</td>
<td>Treatment</td>
<td>None</td>
<td>Kress et al., 2007</td>
</tr>
<tr>
<td>CDDO-Me</td>
<td>Xenograft of Kaposis sarcoma cells</td>
<td>Treatment</td>
<td>None</td>
<td>Vannini et al., 2007</td>
</tr>
<tr>
<td>Liposomal</td>
<td>APL cells from hMRP8-PML/RARα transgenic mice propagated into syngenic FVB-N mice Skin carcinogenesis induced by UV radiation in “high-risk” hairless mice</td>
<td>Prevention</td>
<td>None</td>
<td>Dinkova-Kostova et al., 2008</td>
</tr>
<tr>
<td>CDDO-Me</td>
<td>Xenograft of Dul45 prostate cancer cells in nude rats</td>
<td>Treatment</td>
<td>None</td>
<td>Hyer et al., 2008</td>
</tr>
<tr>
<td>CDDO-Me</td>
<td>MMTV-neu model of ER-breast cancer</td>
<td>Treatment</td>
<td>LG100268</td>
<td>Liby et al., 2008b</td>
</tr>
<tr>
<td>CDDO-Me</td>
<td>Xenograft of PC-3 prostate cancer cells</td>
<td>Treatment</td>
<td>None</td>
<td>Deeb et al., 2009</td>
</tr>
<tr>
<td>CDDO-Me</td>
<td>Lung carcinogenesis induced by vinyl carbamate in A/J mice</td>
<td>Treatment</td>
<td>LG100268 and NRX194204</td>
<td>Liby et al., 2009</td>
</tr>
<tr>
<td>CDDO-EA</td>
<td>Xenograft of MC38 colon cancer cells</td>
<td>Treatment</td>
<td>Tumor-associated antigen vaccine</td>
<td>Nagaraj et al., 2010</td>
</tr>
<tr>
<td>CDDO-Me</td>
<td>Xenograft of L3.6pL human pancreatic cancer cells</td>
<td>Treatment</td>
<td>None</td>
<td>Jutooru et al., 2010</td>
</tr>
<tr>
<td>CDDO-Me</td>
<td>LSL-KrasG12D/+;LSL-Trp53R127H+/+;Pdx1-Cre mouse model of pancreatic cancer</td>
<td>Prevention</td>
<td>LG100268</td>
<td>Liby et al., 2010</td>
</tr>
<tr>
<td>CDDO-EA</td>
<td>Experimental metastasis model –B16F1 melanoma and HT-29 colon cancer cells injected into the mesenteric vein metastasize to the liver</td>
<td>Treatment</td>
<td>None</td>
<td>Townson et al., 2011</td>
</tr>
<tr>
<td>CDDO</td>
<td>Orthotopic injection of primary MMTV-Neu or 4T17 tumor cells into BALB/c or FVB/NJ mice</td>
<td>Prevention</td>
<td>None</td>
<td>Deeb et al., 2011</td>
</tr>
<tr>
<td>CDDO-Im</td>
<td>TRAMP model nanoparticles</td>
<td>Prevention</td>
<td>HER-2 DNA vaccine</td>
<td>Liao et al., 2011</td>
</tr>
<tr>
<td>CDDO-Im</td>
<td>Experimental metastasis model –B16F1 melanoma and HT-29 colon cancer cells injected into the mesenteric vein metastasize to the liver</td>
<td>Treatment</td>
<td>None</td>
<td>Townson et al., 2011</td>
</tr>
<tr>
<td>CDDO-Me</td>
<td>Brca1&lt;sup&gt;+/-&lt;/sup&gt;MMTV-Cre-p53&lt;sup&gt;+/−&lt;/sup&gt; transgenic mouse model of BRCA1-mutated breast cancer</td>
<td>Prevention</td>
<td>None</td>
<td>Kim et al., 2012</td>
</tr>
<tr>
<td>CDDO-Me</td>
<td>PyMT model of ER-breast cancer</td>
<td>Prevention</td>
<td>None</td>
<td>Tran et al., 2012</td>
</tr>
</tbody>
</table>

MMTV, mouse mammary tumor virus; PyMT, polyoma middle T.

CDDO-MA all significantly decrease the number, size, and severity of lung adenocarcinomas (Liby et al., 2007a, 2008a, 2009). When fed in the diet, CDDO-Me and CDDO-EA are especially effective in this model and reduce total tumor burden in the lung by 86 to 98% compared with controls.

In addition to their efficacy in chemical carcinogenesis models, the SOs also significantly delay tumor development in various transgenic mouse models of breast, prostate, and pancreatic cancer. In the mouse mammary tumor virus-neu transgenic model, targeted overexpression of the neu (ErbB2/HER2) receptor tyrosine kinase in the mammary gland drives tumorigenesis. When fed in the diet beginning at 10 weeks of age, CDDO-Me significantly delays tumor development in these mice by over 3 months. Tumor incidence of 50% is observed by 31 weeks of age in the control group but is not reached until 45 weeks in mice fed CDDO-Me (Liby et al., 2008b). In a mouse model in which deletion of the BRCA1 gene (breast cancer associated gene 1) is combined with a mutation in a single allele in the p53 tumor suppressor gene, CDDO-Me significantly delays tumor development. Germline mutations of the BRCA1 gene have been detected in ~90% of familial breast and ovarian cancers, and patients with BRCA mutations have a 50 to 70% lifetime risk of developing ovarian or breast cancer. Tumor burden is also significantly lower in the BRCA1-deficient mice fed CDDO-Me in diet, and lifespan increases an average of 5 weeks compared with control mice. Unlike most cases of the human disease, pErbB2 is overexpressed in cell lines and tumors from these mice. CDDO-Me directly interacts with ErbB2 in vitro and inhibits its constitutive phosphorylation in vitro and in vivo (Kim et al., 2012). In a TRAMP model, oral gavage...
of CDDO (10 \( \mu \)mol/kg) for 20 weeks does not prevent the development of preneoplastic prostate lesions but does inhibit the pathological progression to adenocarcinomas and reduces metastasis. Several proteins involved in apoptosis, including Bcl-2, Bcl-X\(_L\), survivin, and cellular inhibitor of apoptosis protein, are lower in the prostates of the TRAMP mice treated with CDDO than in prostates from control mice (Deeb et al., 2011). In the KPC (LSL-KrasG12D/+:LSL-Trp53R127H/++;Pdx-1-Cre) model of pancreatic cancer, activating mutations in the Kras and p53 oncogenes are targeted to the pancreas, and these mice develop pancreatic lesions that rapidly progress to invasive and metastatic adenocarcinomas. CDDO-Me, alone or in combination with the rexinoid LG100268, extends survival in KPC mice by a relatively modest 3 to 4 weeks. In comparison, gemcitabine, the standard of care for pancreatic cancer, has no effect in this aggressive mouse model. In pancreatic cancer cell lines derived from KPC tumors, the SOs interact with STAT3 and IKK and block constitutive IL-6 secretion, STAT phosphorylation, and IKK activity (Liby et al., 2010). It is noteworthy that there is no evidence that long-term administration of CDDO for 20 weeks by oral gavage in the TRAMP model or CDDO-Me in diet for 35 to 45 weeks in the other transgenic mouse models enhances tumorigenesis.

In contrast to many other diseases, the ability of the SOs to prevent cancer in experimental animals may not be primarily through Nrf2 signaling. With the exception of the aflatoxin studies (Yates et al., 2006), the SOs were not administered until at least 1 week after challenge with a carcinogen, suggesting that the SOs were not simply preventing cancer by detoxifying the original insult before it could initiate DNA damage. The Nrf2/ARE pathway was important for prevention of carcinogenesis by the SOs in the liver (Yates et al., 2006) and skin (Dinkova-Kostova et al., 2008), but there is no evidence that this pathway is required for efficacy in the other prevention studies. In fact, several recent studies suggest that activation of the Nrf2/ARE pathway in cancer cells may be detrimental and contribute to resistance to chemotherapy or radiation (Taguchi et al., 2011). In several human cancer cell lines or tumors, mutations in Keap1 or Nrf2 result in constitutive activation of the pathway, causing an adaptive stress response and a survival advantage. Moreover, two recent studies used animal models in which mutations in the Kras proto-oncogene activate Nrf2 and drive tumorigenesis (Bauer et al., 2011; DeNicola et al., 2011); Kras mutations are thought to occur in human cancers at a higher rate than mutations in Keap1 or Nrf2. The emerging importance of Nrf2 and cancer is obviously relevant to SOs biology and has been reviewed extensively (Sporn and Liby, 2012). However, it is important to note that genetic activation of a pathway is far different from pharmacological activation in terms of the duration and amplitude of the response (Kensler and Wakabayashi, 2010). This fact has been verified experimentally; the global expression patterns vary significantly when comparing microarray results from the livers of mice treated with CDDO-Im versus mice in which Keap1 is deleted (Yates et al., 2009). Moreover, the SOs are useful for preventing and treating cancer in a variety of experimental models (Table 4), including models in which mutations in Kras drive carcinogenesis (Liby et al., 2007a, 2010).

2. Treatment. In addition to their efficacy for prevention of cancer, the SOs have been used to treat established tumors in experimental models. As suggested by the number of published studies on SOs and leukemia (summarized in Table 1), leukemia cells seem to be especially sensitive to triterpenoids. When BDF1 mice injected with L1210 leukemia cells are treated with 100 \( \mu \)g/day CDDO or CDDO-Im, the number of leukemia cells decreases by 81 to 91% (Place et al., 2003), and similar antitumor effects are observed with B16 melanoma cells. The overexpression of Bcl-2 and mutations in TRAF2 are commonly found in human chronic lymphocytic leukemia (CLL), and when these alterations are introduced into B cells in mice, they develop small B-cell lymphoma and CLL. When liposomes containing CDDO or CDDO-Im are injected intravenously into TRAF2DN/Bcl-2 mice with active CLL, the SOs apoptose the malignant cells. CDDO-Im is more potent than CDDO and reduces tumor burden of circulating B cells by 60 to 90% (Kress et al., 2007). In a syngeneic mouse model of APL in which leukemic blasts from hMRP8-PML/RAR\(\alpha\) transgenic mice are injected into FBV-N mice, liposomal CDDO-Me enhances differentiation induced by a subtherapeutic dose of ATRA in established APL cells; the combination of ATRA and CDDO-Me also significantly extends survival (Tabe et al., 2007).

Despite concerns about the predictability and relevance of xenograft models, which lack appropriate immune and stromal components, the injection of human cancer cells into immunodeficient mice remains a standard model for testing cancer drugs. The SOs are active in xenograft models of breast cancer (Lapillonne et al., 2003; Konopleva et al., 2006; Liao et al., 2011), Kaposi's sarcoma (Vannini et al., 2007), prostate cancer (Hyer et al., 2008; Deeb et al., 2009), colon cancer (Nagaraj et al., 2010), and pancreatic cancer (Jutooru et al., 2010). However, significant antitumor activity against established tumors is more evident when a triterpenoid is combined with other drugs, such as TRAIL (Hyer et al., 2005), ATRA (Tabe et al., 2007), rexinoids (Liby et al., 2009), or vaccines (Nagaraj et al., 2010; Liao et al., 2011). In an immunocompetent mouse model of breast cancer, chemoresistant 4T1 cells, derived from a spontaneous mammary tumor, are injected back into BALB/c mice to study primary tumors as well as metastases. When treatment with CDDO-Me in liposomes is started 1 day after the injection of 4T1 cells, the drug completely blocks tumor formation and metastasis. Tumor size is also significantly smaller in the mice treated with CDDO-Me than in the control group, even when treat-
ment is delayed until 5 days after inoculation of the aggressive 4T1 cells. Moreover, the population of mature dendritic cells in BALB/c mice with 4T1 tumors decreases by two thirds compared with BALB/c mice without tumors, but CDDO-Me helps maintain the number of mature dendritic cells in this model (Ling et al., 2007).

The triterpenoids may also prevent metastasis. In vitro, SOs inhibit cell migration by targeting cytoskeletal proteins (To et al., 2008, 2010). CDDO-Me not only inhibits the invasion of 4T1 breast cancer cells into a matrix but also eliminates metastasis to the lungs when these cells are injected into BALB/c mice (Ling et al., 2007). CDDO also reduces the incidence of metastasis to liver and lymph nodes in the TRAMP model of prostate cancer (Deeb et al., 2011). In both the 4T1 and TRAMP models, however, the SOs also suppress tumor growth, so it is possible that the antimitotic effects of the SOs in these models are the result of a lower primary tumor burden, which reduces the number of cells available to metastasize. To address this issue, B16F1 melanoma cells and HT-29 colon cancer cells were directly injected into the mesenteric vein of mice. Once cells had colonized in the liver, the mice were fed a diet containing CDDO-Im for 8 weeks, and the treatment with the SOs reduced the metastatic burden of the HT-29 cells by 70%. CDDO-Im also lowered the tumor burden of the B16F1 melanoma cells in the liver by 50% but did not reduce the number of individual cells, suggesting that the drug inhibits proliferation of the malignant cells once colonized in the liver but did not induce apoptosis (Townson et al., 2011).

3. In Vivo Anticancer Mechanisms. As mentioned previously, numerous mechanisms have been proposed to explain the growth inhibitory and apoptotic effects of the SOs for the treatment of cancer. However, these studies are based primarily on in vitro data, and there is little evidence that many of these mechanisms occur in vivo. Important biomarkers of anticancer efficacy for the SOs that have been validated in vivo include pSTAT3 (Ling et al., 2007; Liao et al., 2011), pHER2/pErbB2 (Konopleva et al., 2006; Kim et al., 2012), and pAKT (Deeb et al., 2011). The SOs decrease either the expression or the activity of all of these proteins, which are overexpressed or constitutively activated in many human cancers (Yu et al., 2009; Baselga, 2010; Grivennikov and Karin, 2010; Li et al., 2011). There are undoubtedly other targets and pathways that account for the effects of SOs on established cancers, but new mechanistic studies will require additional experiments and analysis in relevant animal models.

In addition to directly targeting tumor cells, the SOs have effects on a variety of stromal cells. Targeting tumor vasculature is an attractive strategy for treating cancer because angiogenesis is required for both tumor growth and metastases (Carmeliet and Jain, 2011; Weis and Cheresh, 2011), and CDDO-Me reduces the expression of MMP-9, VEGF, CXCL12, and CCL2 from tumor cells (Shishodia et al., 2006; Tran et al., 2012). This SO also inhibits the ability of human umbilical vein endothelial cells to proliferate and form capillary-like networks in vitro and is reportedly active at doses as low as 3 μg/kg of body weight for blocking angiogenesis induced by VEGF and TNFα in a Matrigel sponge assay (Vannini et al., 2007). CDDO-Me and CDDO also reduce the number of CD31-positive blood vessels in a Kaposi’s xenograft model and in the TRAMP model, respectively (Vannini et al., 2007; Deeb et al., 2011).

Several recent studies also report that the SOs can target immune cells. Although maintaining levels of dendritic cells, as CDDO-Me does in the 4T1 breast cancer model (Ling et al., 2007), is beneficial in cancer therapy, tumors often hijack the immune system to secrete cytokines and growth factors that promote angiogenesis, tumor growth, and survival (Mantovani et al., 2008; Grivennikov et al., 2010; Qian and Pollard, 2010; Ruffell et al., 2010). MDSCs promote tumor angiogenesis and invasion and suppress T-cell mediated immunosuppression of cancer cells (Ostrand-Rosenberg, 2010; Youn and Gabrilovich, 2010). In an animal model and in MDSCs from patients treated with bortezomib, the drug blocks the activity of MDSCs, as measured by nitrotyrosine levels and T-cell responsiveness, but not the number of MDSCs. As a result, CDDO-Me may favorably improve antitumor immune function, especially when combined with a cancer vaccine (Nagaraj et al., 2010). MDSCs also suppress peptide binding to major histocompatibility complex proteins and thus prevent an antigen-specific CTL response to tumor cells. Although CDDO-Me does not affect peptide binding, it does eliminate the protective effect against a lethal CTL response and thus enhances killing of the tumor cells by T lymphocytes (Lu et al., 2011). In an orthotopic 4T07 model of breast cancer, CDDO-Im increases expression of pSTAT1, IL-15, IL-12b, and granulocyte macrophage colony-stimulating factor and decreases expression of IL-6, IL-16, and TGF-β, suggesting a Th1 response. This shift from a pro-tumor Th2 response to an antitumor Th1 phenotype is accompanied by the infiltration of activated CD8+ T cells, M1 macrophages, and dendritic cells. When CDDO-Im treatment is combined with a HER-2 vaccine, significant protection against tumor recurrence and an enhanced tumor-specific CTL response are observed (Liao et al., 2011).

The ability of SOs to modulate immune cells and other components of the tumor microenvironment suggest they should be tested in combination with immunomodulatory vaccines, antiangiogenic agents, or chemotherapeutic drugs. The triterpenoids are not conventional cytotoxic agents and frequently do not display potent apoptotic activity against established solid tumors, so their usefulness as cancer drugs might be enhanced if combined with radiation or chemotherapy (Shishodia et al., 2006). This approach could exploit the altered levels of oxidative stress in tumor cells versus...
normal cells for therapeutic benefit (Trachootham et al., 2006, 2009; Acharya et al., 2010; Montero and Jassem, 2011). Preliminary studies suggest that CDDO-Me can simultaneously enhance the antitumor effect of radiation against tumor xenografts and protect normal tissue against mucositis (Meyer et al., 2006). Ongoing studies are attempting to confirm and extend these provocative data. Moreover, additional work with the SOs may enable the exploitation of real differences between normal and cancer cells (Trachootham et al., 2009; Acharya et al., 2010). In this scenario, up-regulation of Nrf2 cytoprotective pathways by the SOs could protect normal cells and tissues without inhibiting the induction of oxidative stress by radiation or chemotherapeutic drugs required to apoptose cancer cells. The possibility that the SOs increase platelet production and myelopoiesis (Petronelli et al., 2011; Sardina et al., 2011; Ames et al., 2012) are especially germane to this hypothesis.

VI. Signaling Pathways and Mechanisms of Action

As described above, the SOs are multifunctional drugs that not only suppress inflammatory and oxidative stress, and are thus cytoprotective, but also inhibit cell proliferation and induce differentiation or apoptosis. These biological responses are dose-responsive, as summarized in Fig. 3. As would be expected based on their pleiotropic nature, pentacyclic triterpenoids, both natural and synthetic, interact with many different protein targets and signaling pathways. This is not surprising, given the evolutionary origin of these isoprenoid molecules. Their hydrophobic nature provides high overall affinity for membrane structures in the cell, as well as for individual hydrophobic side chains on specific target proteins. The natural terpenoids have been interacting with animal cells for millennia; now, in the case of the SOs, the chemist has added new mechanisms of interaction by introducing cyano-enone functions that provide specific mechanisms for formation of covalent bonds, either reversibly or irreversibly, with reactive cysteine residues on target proteins. However, despite this multifunctionality, these agents do not seem to be cytotoxic, as has been demonstrated amply in numerous studies in both animals and humans. As described in this section, many such targets have been identified by either cell biology or proteomic analysis.

Modifying OA by the addition of α,β-unsaturated carboxyl groups in the A and C rings and an electron-withdrawing nitrile group at C2 enhances the possibility of Michael addition to C1. Structure-activity analysis suggests that the maintenance of this Michael acceptor position is required for the potent anti-inflammatory activity of the SOs (Sporn et al., 2011). The presence of an enone group and its position in the C ring are also essential for induction of NQO1 enzyme activity. The introduction of a second enone functionality in the C ring (TP-82) enhances activity 10-fold compared with its inclusion in the A ring alone (TP-46) (Fig. 1C). Moreover, if this enone group in the C ring is moved from the 9(11)-en-12-one position, as found in CDDO-Me, to the 12-en-11-one position (TP-162), potency decreases 100 fold (Fig. 1C). The inclusion of a double bond between C12-C13 coupled with the complete elimination of the ketone group in the C ring (TP-156) is 1500-fold less active than CDDO-Me (Dinkova-Kostova et al., 2005).

![Fig. 3. Biological responses to SOs are dependent on dose. Low concentrations (nanomolar) of SOs target Keap1 and activate the Nrf2/ARE cytoprotective and anti-inflammatory response. As the concentration of SO increases, SOs target Arp3 and other components of the cytoskeleton to inhibit cell proliferation, whereas even higher concentrations (micromolar) of SOs can selectively induce apoptosis in cancer cells by targeting a number of key regulatory proteins and pathways that are frequently constitutively activated or overexpressed in cancer cells. [Adapted from Liby KT, Yore MM, and Sporn MB (2007) Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 7:357–369. Copyright © 2007 Nature Publishing Group. Used with permission.]](image-url)
However, the SOs do not interact nonspecifically with all proteins containing cysteines, as discussed in greater detail in section VI.H. Instead, the nucleophilicity of the –SH group of cysteine is markedly influenced by the accessibility of a drug to a specific cysteine residue as well as the redox potential of the cell (Jones, 2010; Paulsen and Carroll, 2010).

A. Kelch-Like Erythroid Cell-Derived Protein with CNC Homology-Associated Protein 1 (Keap1)

The varied biological activities of the SOs are possible because of their ability to interact with cellular nucleophiles such as the –SH groups of cysteines on target proteins, as has been confirmed in a number of studies. When CDDO is incubated with nucleophiles such as dithiothreitol (DTT), cysteine or reduced glutathione, the resulting spectral shift and hypochromism indicate a direct interaction (Couch et al., 2005; Liby et al., 2007b).

A similar spectral shift is observed when di-CDDO (TP-225) is incubated with either DTT or Keap1, the inhibitor of Nrf2. Although mouse and human Keap1 contains 25 or 27 Cys residues, respectively, not all Cys residues have identical reactivities (Dinkova-Kostova et al., 2002; Yamamoto et al., 2008), and various Nrf2 inducers may interact with different cysteines and through different mechanisms (Kobayashi et al., 2009; Giudice et al., 2010; Kansanen et al., 2011). Three SOs also compete with [3H]Dexamathasone 21-mesylate for binding to Keap1, suggesting a direct interaction between SOs and Keap1 and that Keap1 acts as a molecular sensor for activation of the Nrf2 pathway by the SOs (Dinkova-Kostova et al., 2005).

The activation of the Nrf2 pathway remains a key target for understanding the mechanism of action and biology of the SOs. The elucidation of the specific cysteine residues in Keap1 that are binding sites for SOs is an active area of investigation, as is the possibility that SOs can activate Nrf2 by additional mechanisms beyond direct interaction with Keap1. However, it should also be noted that not all of the anti-inflammatory and cytoprotective properties of the SOs necessarily involve activation of the Nrf2 pathway. For example, the SOs are potent inducers of the HO-1 protein, and binding of Nrf2 to the ARE on the promoter region of this gene are only partially responsible for its induction by the SOs (Liby et al., 2005). The HO-1 enzyme and its downstream effectors are “druggable” targets (Mancuso and Barone, 2009), because induction of HO-1 is protective in many organs, including the cardiovascular system (Wu et al., 2011a), kidney (Abraham et al., 2009), lung (Raval and Lee, 2010), and brain (Jazwa and Cuadrado, 2010) against a variety of diseases. It is noteworthy that intracerebroventricular infusion of CDDO-Im enhances survival of neurons and decreases infarct volume in rats challenged by global or focal ischemia. Concomitant administration of tin protoporphyrin IX, a competitive inhibitor of the HO-1 enzyme, abrogates the protective effects of CDDO-Im, demonstrating the importance of HO-1 induction for its efficacy in these stroke models (Zhang et al., 2012). Moreover, the SOs can induce phosphorylation of Akt, which may be involved in protection of retinal pigment epithelial cells (Piha-Rowe et al., 2009) and potentially other normal cells as well. It is also possible that the SOs inhibit Toll-like receptor signaling, which regulates inflammation and tissue repair after injury (Rakoff-Nahoum and Medzhitov, 2009), but this hypothesis has not been tested directly.

B. Peroxisome Proliferator-Activated Receptor γ (PPARγ)

Although Keap1 is an important direct target of the SOs, it was not the first molecular target to be identified. Because of its ability to induce differentiation of adipocytes, CDDO was evaluated as a ligand for PPARγ. In scintillation proximity assays, both CDDO and CDDO-Me compete with purified PPARγ for bound [3H]CDDO (Kᵢ of 310 nM for CDDO versus 50 nM for the known PPARγ ligand rosiglitazone), but DTT interrupts this interaction. Although both CDDO and CDDO-Me are ligands for PPARγ, neither binds to PPARα (Wang et al., 2000); in contrast CDDO-Im binds to both receptors (Place et al., 2003). Although CDDO can transactivate both a wild-type PPARγ receptor as well as a chimeric PPARγ protein construct transfected into CV1 cells, CDDO-Me did not activate either of these constructs, apparently because of differences in the recruitment of the coactivator CBP and interactions with nuclear receptor corepressor 1 (Wang et al., 2000). However, in colon cancer cells, CDDO, CDDO-Me, and CDDO-Im all transactivate a PPARγ reporter construct (Chintharlapalli et al., 2005). The effects of the SOs on proliferation and apoptosis of these colon cancer cells were attributed to both PPARγ-dependent and -independent mechanisms, and several other investigators have suggested that SO-PPARγ interactions may decrease levels of cyclin D1 or induce caveolin-1 (Lapillonne et al., 2003; Konopleva et al., 2006). PPARγ has been suggested as a possible therapeutic target for diseases as diverse as diabetes, atherosclerosis, hypertension, chronic kidney disease, and cancer (Glass, 2006; Glass and Ogawa, 2006; Schmidt et al., 2010; Sugawara et al., 2010). It is noteworthy that 15-deoxy-Δ12,14-PGJ2 covalently binds to a cysteine residue in the ligand binding pocket of PPARγ through Michael addition (Shiraki et al., 2005); the ability of an SOs to interact with this Cys residue has not been confirmed.

C. Inhibitor of Nuclear Factor-κB Kinase Complex (IKK) and the Nuclear Factor-κB Pathway

The NF-κB pathway is another important target of the SOs. This transcription factor activates a number of genes that promote inflammation, proliferation, and survival, and because it regulates the inflammatory mi-
croenvironment, this pathway can promote tumorigenesis (Karin, 2009; Grivennikov et al., 2010; Ben-Neriah and Karin, 2011). Although numerous studies report that the SOs inhibit this pathway (Stadheim et al., 2002; Ahmad et al., 2006; Ray et al., 2006; Shishodia et al., 2006; Yore et al., 2006; Nichols et al., 2009; Hogan et al., 2011), the direct target in the NF-κB pathway for the SOs was not known until biotinylated SOs were synthesized (Honda et al., 2004) and used to show direct interaction with protein targets. The SOs directly interact with Cys179 on IkB kinase β (IKKβ) and inhibit its kinase activity (Ahmad et al., 2006; Yore et al., 2006). IKKβ is the kinase that phosphorylates IkBα, causing its degradation and the subsequent translocation of NF-κB p65 to the nucleus. Although the NF-κB pathway is often proinflammatory, higher concentrations of SOs (0.3–1 μM) are typically needed to inhibit this pathway than to inhibit the production in vitro of the proinflammatory cytokines (0.001–0.1 μM) summarized in Table 1. As discussed previously, the anti-inflammatory activities of the SOs are more likely to be the result of activation of the Nrf2 pathway rather than direct inhibition of IKK and the NF-κB pathway itself. The inhibition of IkBα degradation by the SOs is more evident in cancer cells than in immune cells (Liby et al., 2008b), and inhibition of this pathway may be a useful marker of anticancer activity (Liby et al., 2009, 2010; Deeb et al., 2011) in cells with constitutive activation of NF-κB.

D. Janus Tyrosine Kinase/Signal Transducer and Activator of Transcription (JAK/STAT)

In addition to suppressing pro-survival signaling through the NF-κB pathway, the SOs also reduce phosphorylation of STAT proteins at similar concentrations needed to inhibit the NF-κB pathway (0.3–1 μM). STATs are transcription factors known to contribute to cellular transformation, proliferation, survival, invasion, and metastasis, and STAT3 is constitutively activated in many types of cancers (Yu et al., 2009; Grivennikov and Karin, 2010). After ligand binding to growth factor receptors, such as the IL-6 receptor, a Janus-activated kinase (JAK) phosphorylates the receptor, allowing recruitment and phosphorylation of a STAT. STATs then dimerize, translocate to the nucleus, and induce transcription of numerous STAT targets, including cyclin D1, myc, and survivin proteins. The SOs rapidly inhibit STAT3 or STAT5 phosphorylation, either constitutive or induced by IL-6 stimulation, in myelomas, osteosarcomas, and lung or breast cancer cells in vitro (Liby et al., 2006, 2007, 2008b; Ahmad et al., 2008; Ryu et al., 2010b) or in vivo (Liao et al., 2011). By directly interacting with Cys1077 on JAK1, CDDO-Me not only suppresses JAK1 phosphorylation but also inhibits its ability to phosphorylate STAT3 and induce STAT3 dimerization (Ahmad et al., 2008). Moreover, the SOs form adducts with STAT3 through interaction with Cys259, suggesting that the potent inhibition of the JAK-STAT pathway by the triterpenoids occurs because of direct inhibition of two different key proteins in the pathway. More recent studies suggest that the SOs reduce IL-6 secretion and inhibit STAT3 phosphorylation in ovarian (Duan et al., 2009) or pancreatic (Liby et al., 2010) cancer cells; the secreted IL-6 may act as a survival factor to drive constitutive activation of the JAK-STAT pathway in these cells (Neurath and Finotto, 2011). In addition to their direct inhibition of JAK and STAT, CDDO-Im also indirectly modulates this signaling pathway by up-regulating negative regulators of the STATs, such as SOCS1 (suppressor of cytokine signaling 1) and the tyrosine phosphatase SHP1 (Liby et al., 2006). Because STAT3 regulates a number of genes important in both wound healing and cancer (Dauer et al., 2005), it is possible that the SOs have different effects on JAK-STAT signaling at lower concentrations than used for the studies described above or in a physiological context of acute inflammation and healing rather than cancer. To date, these important studies have not been performed.

E. Human Epidermal Growth Factor Receptor 2 (HER2)/ErbB2/neu

Overexpression of HER2/ErbB2/neu is found in as many as 25 to 30% of breast cancers (Baselga, 2010; Gutierrez and Schiﬀ, 2011). Because of the aggressiveness of this form of breast cancer, prognosis was poor until the introduction of drugs, such as trastuzumab (Herceptin), that inhibit this receptor tyrosine kinase. CDDO reduces phosphorylation of HER2 in breast cancer cells that overexpress this receptor and inhibits its kinase activity in vitro and in vivo (Konopleva et al., 2006). Although a direct effect on ErbB2 itself was not examined, CDDO-Me signiﬁcantly delays tumor development and the growth of established tumors in mouse mammary tumor virus-neu mice in which neu overexpression drives tumorigenesis (Liby et al., 2008a). In a mouse model of BRCA-deﬁcient breast cancer, ErbB2 expression increases over time in both the mammary gland and in tumors, and CDDO-Me not only directly interacts with this protein but also inhibits its phosphorylation (Kim et al., 2012).

F. Phosphatase and Tensin Homolog (PTEN) and the Phosphatidylinositol 3-Kinase/Protein Kinase B (PI3K/Akt) Pathway

The phosphatidylinositol 3-kinase (PI3K)/AKT pathway plays an important role in regulating cell division and death (Bunney and Katan, 2010; Vanhaesebroeck et al., 2010), and the loss of activity of the tyrosine phosphatase PTEN results in constitutive activation of the PI3K/Akt pathway (Hollander et al., 2011). Treating U937 leukemia cells with CDDO-Im induces a transient phosphorylation of Akt, but the PI3K inhibitor 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) blocks the induction of HO-1 by the SOs in these cells (Liby et al., 2005). Likewise, CDDO-Im induces Akt
phosphorylation in retinal pigment epithelial cells, but inhibition of Akt activation by LY294002 prevents the cytoprotective benefit of CDDO-Im for survival against oxidative stress induced by tBHP (Pitha-Rowe et al., 2009). A biotinylated SO directly interacts with PTEN, and this interaction is functionally significant because CDDO-Im suppresses, in a dose-dependent manner, the lipid phosphatase activity of PTEN. Moreover, the introduction of a Ser mutation at Cys124 interferes with the binding of the biotinylated SOs to PTEN, suggesting that SOs activate Akt by binding to Cys124 within the active site of PTEN and inhibiting its activity. It is interesting to note that induction of cytoprotective pathways by the SOs involves interacting with Keap or PTEN and the subsequent activation of Nrf2 and Akt, whereas an interaction with constitutively overexpressed IKK, ErbB2, or JAK/STAT by the SOs inhibits the pathway and thus reduces proliferation and/or induces apoptosis.

Although the activation of the Akt/PI3K pathway may be beneficial in normal retinal epithelial cells or in neurons to enhance survival, this pathway is often overexpressed or activated in cancer cells (Engelman, 2009), often through the loss of activity of its inhibitor PTEN (Hollander et al., 2011). Numerous inhibitors of the pathway are being evaluated in clinical trials for the treatment of cancer (Bunney and Katan, 2010; McNamara and Degterev, 2011; Shuttleworth et al., 2011). In cancer cells (Deeb et al., 2007, 2011; Ling et al., 2007; Liu et al., 2012) and in myofibroblasts stimulated with TGFβ (Kulkarni et al., 2011), the SOs inhibit Akt phosphorylation. The dose of SOs used in these experiments is important for explaining these opposing effects on Akt phosphorylation. Although 100 nM CDDO-Im enhances Akt phosphorylation (Liby et al., 2005; Pitha-Rowe et al., 2009), minimum concentrations of 0.5 μM (Ling et al., 2007; Kulkarni et al., 2011) or higher (Deeb et al., 2007, 2008; Liu et al., 2012) of CDDO or CDDO-Me are required to inhibit its phosphorylation. Similar high concentrations of SOs inhibit Akt kinase activity without affecting its upstream kinase PDK1 (Liu et al., 2012).

**G. Mammalian Target of Rapamycin (mTOR)**

In addition to the studies described above on the PI3K/Akt pathway, a proteomics analysis of potential SO binding partners found that several components of the PI3K/akt/mTOR pathway are highly enriched, suggesting that mTOR may be a triterpenoid target (Yore et al., 2011). A biotinylated SO directly interacts with mTOR, and 250 nM CDDO-Im inhibits insulin-induced phosphorylation of S6 kinase, 4-EBP, P70S6 kinase, and mTOR without suppressing phosphorylation of Akt. Moreover, an in vitro kinase assay demonstrates that CDDO-Im inhibits the insulin-induced phosphorylation of mTOR. In prostate cancer cells in which the PI3K/ Akt/mTOR pathway is constitutively expressed because of mutations in PTEN, CDDO-Im also inhibits phosphorylation of S6 and 4-EBP but not Akt. Because of its role as a sensor of energy balance, cellular stress, growth factors, and nutrient abundance, deregulation of the mTOR pathway contributes to diseases such as diabetes, aging, and cancer (Zoneu et al., 2011). Rapamycin, which targets the mTOR complex 1, is an FDA-approved drug for immunosuppression after organ transplantation and inhibits proliferation of smooth muscle cells after implantation of coronary stents, but several new mTOR inhibitors (Benjamin et al., 2011; Wander et al., 2011) are being developed for cancer and metabolic disorders such as diabetes.

**H. Thiol Proteome**

Based on the known biology of the triterpenoids, Keap1, PPARγ, IKK, JAK1, STAT3, ErbB2, PTEN, and mTOR were all shown to be direct, valid targets of the SOs. The response of these proteins to the SOs is rapid; changes can be detected within 15 to 60 min and thus before gene transcription and translation can occur. A biotinylated SO or binding studies with recombinant proteins have been used to show direct interactions, and biological effects on the proteins themselves, usually through kinase assays, or their respective downstream pathways confirm the relevance of the pathways to SO biology. It is noteworthy that all of these protein targets contain reactive cysteine residues, which play a critical role in the cellular function. On the basis of the structures of the SOs and the importance of two electrophilic Michael acceptor sites in the A and C rings for activity, it is anticipated that SOs should be able to interact with other proteins containing structurally available, redox-sensitive cysteine residues. It is also possible that a “cysteine code” allows for different reactivities of cysteine residues on target proteins that regulate unique downstream pathways (Kobayashi et al., 2009), potentially explaining the dose response observed with the SOs. To identify other putative protein targets of the SOs, a biotin-tagged triterpenoid was used to treat intact cells and then used as a probe to affinity-purify interacting proteins. More than 500 proteins were identified by liquid chromatography-tandem mass spectrometry in this unbiased proteomics snapshot (Yore et al., 2011), including the known SOs targets IKK, JAK1, and PTEN. When annotated by biological processes, these putative targets primarily function in processes of metabolism, transcription, cell cycle, and signal transduction. If the targets are categorized based on molecular function gene ontology identifiers, more than 75% of the proteins are involved in kinase or catalytic activity, transcription, or regulation of enzyme activity. Moreover, these proteins form a highly interconnected network, suggesting that the SOs do not interact nondiscriminately with random Cys residues in every protein in the cell.

A number of factors affect the reactivity of a Cys residue on a target protein and its ability to interact...
reversibly with a SO. Basic amino acids in close proximity to a Cys residue on a protein enhance its reactivity, and side chains or a bulky scaffold may limit access to a binding pocket on a protein. The pH of the local subcellular compartment, hydrophobicity, electrostatic interactions, the redox status of the cell, and allosteric considerations are other factors that regulate Cys reactivity (Doulias et al., 2010; Vazquez-Torres, 2012). The relevance of these issues for SO biology has been reviewed recently (Sporn et al., 2011). Because of this complex biology, experiments in which thiol-containing reagents such as DTT, 2-mercaptoethanol, or N-acetyl cysteine are used to reverse the effects of the SOs must be interpreted with caution, because the resulting interaction between the triterpenoid and –SH group may simply prevent interaction with a cellular target instead of inhibiting the effect. The targeting of cysteine residues on proteins by a multifunctional compound (Na and Surh, 2006; Zhao et al., 2011) such as an SO is not without precedent; endogenous cyclopentenone prostaglandins (Kim and Surh, 2006; Surh et al., 2011) and multifunctional natural products such as sulforaphane and isothiocyanates (Clarke et al., 2008; Cheung and Kong, 2010; Brown and Hampton, 2011), avicins (Haridas et al., 2004; Haridas et al., 2005), and celastrol (Kannayaian et al., 2011) also act through similar mechanisms. Indeed, intracellular redox signaling may be tightly regulated via a “thiolstat” to allow cells to respond reversibly to oxidative changes in a measured and appropriate manner (Janssen-Heininger et al., 2008; Paulsen and Carroll, 2010; Finkel, 2011; Jacob, 2011). Although drugs that covalently interact with proteins were avoided because of safety concerns early in the era of “targeted therapy,” the prevalence and apparent safety of useful covalent drugs has resulted in a resurgence in this field (Singh et al., 2011). Because of the importance of redox-sensing thiols in signaling and disease (Jones, 2010), the proteins that compose or regulate this signaling network are currently being targeted for drug development (Montero and Jassem, 2011).

A number of additional possible protein targets for the SOs have been reported using the biotinylated triterpenoid pulldown approach. These include the following proteins: protein kinase A, ataxia- and Rad-related-2, ataxia telangiectasia mutated, retinoid X receptor α, AMPK (Yore et al., 2011), cAMP response element-binding protein, CCAT/enhancer-binding protein β, cyclin D1, and epidermal growth factor receptor (Liby et al., 2009, 2010; Tran et al., 2012). Mitochondrial glutathione (Samudio et al., 2005), the mitochondrial protease Lon (Bernstein et al., 2012), and a limited number of thiol-containing mitochondrial proteins (Brookes et al., 2007) have also been studied using a biotinylated triterpenoid. The SOs also directly interact with tubulin and actin (Couch et al., 2006; To et al., 2010), but the physiological consequences of these interactions are less apparent because very high concentrations of SOs (30–50 μM) are required to disrupt polymerization of these proteins. Moreover, mere interaction of a protein with a biotinylated SO does not ensure functionality. Protein complexes can be identified through proteomics analysis, and SOs can interact with proteins without changing any downstream signaling. The potential relevance of many of these proteins in diseases, however, suggests that additional studies are needed to determine the effects of the SOs on these proteins and pathways. The possibility that SOs interact with different targets in different cell types, that binding affinities to the SOs differ depending on the protein, and that protein abundance and SOs concentrations contribute to the biological complexity are still under investigation.

I. Transforming Growth Factor-β Pathway

In addition to the direct targets that have been identified, the SOs also affect other important signaling pathways. Like the multifunctional SOs, the TGF-β superfamily regulates physiological processes as diverse as inflammation and immunity, cell proliferation and migration, and differentiation and apoptosis (Bierie and Moses, 2010; Ikushima and Miyazono, 2010; Santibañez et al., 2011). CDDO and CDDO-Im increase mRNA expression of the type II TGF-β receptor and prolong Smad2 phosphorylation induced by TGF-β in leukemia cells (Suh et al., 2003a). The effects of the SOs on the TGF-β superfamily are most noticeable when coincubated with TGF-β, and this combination enhances promoter activity for TGF-β, activins, and BMPs. The prolonged Smad2 phosphorylation after treatment with CDDO-Im accompanies delays in the degradation of the TGF-β receptor, changes in microtubule dynamics, altered trafficking, and inhibition of TGF-β-dependent migration but is independent of Smad2 phosphatase activity (To et al., 2008). A biotinylated SO localizes to the leading edge polarity complex on migrating cells and alters the organization of microtubules and their attachment to the polarity complex by interfering with Clip-170, a microtubule-capping protein that regulates membrane association. By interacting with Arp3 and other proteins in the actin cytoskeletal complex, the SOs also disrupt the localization of these proteins and thus inhibit actin polymerization and migration (To et al., 2010). In Smad3(−/−) fibroblasts or after overexpression of Smad7, the ability of CDDO to inhibit MMP1 and MMP13 promoter activity is partially reversed (Mix et al., 2004). During the induction of monocytic differentiation by CDDO-Im, the triterpenoid activates phosphorylation of Erk1/2 and Smad1, -3, and -5 and increases mRNA expression of BMP-6, BMP receptor II, TGF-β2 and TGF-β receptor II (Ji et al., 2006). The mitogen-activated protein kinase kinase inhibitor 2'-amino-3'-methoxy flavone (PD98059), antibodies against TGF-β, and the BMP antagonist noggin all partially inhibit differentiation induced by CDDO-Im. Moreover, both CDDO-Im and CDDO-EA induce chondrogenesis in...
newborn mouse calvaria and up-regulate genes involved in this process, including SOX9, BMPs, Smads, and TIMPs (Sub et al., 2012). Context is again important, however, because the triterpenoids can also reduce the secretion of TGF-β (Liao et al., 2011) or inhibit its effects. In pulmonary fibrosis or in corneal scarring, TGF-β drives the differentiation of fibroblasts into myofibroblasts, but the SOs inhibit both the differentiation of these cells and the subsequent TGF-β-dependent production of collagen and other matrix components (Ferguson et al., 2009a; Kulkarni et al., 2011; Kuriyan et al., 2012). Despite these observations, no proximate direct interaction between a SO and any member of the TGF-β pathway has yet been identified.

J. Other Pathways

Although numerous microarray studies have revealed the importance of activation of Nrf2 by the triterpenoids (Lapillonne et al., 2003; Liby et al., 2005; Yates et al., 2006; Yates et al., 2009), other genes and signaling pathways are also affected and undoubtedly contribute to the mechanism of action of the SOs. A number of natural triterpenoids regulate glucose and lipid metabolism (Sheng and Sun, 2011), and the SOs also regulate a number of genes involved in metabolism (Yates et al., 2009). Single studies also suggest the possible importance of glycogen synthase kinase 3β (Véné et al., 2008), fatty acid synthase (Hughes et al., 2008), specificity proteins (Jutooru et al., 2010), and phospho-Chk1 and phospho-Chk2 (Kim et al., 2011) to SO activity, but additional work is needed to confirm the biological relevance of these proteins and to address whether they are direct targets or downstream of the targets discussed previously. Moreover, the triterpenoids clearly induce apoptosis of cancer cells, but neither the direct target of the SOs nor the initiating event for starting this cascade has been identified.

To add to the complexity of the biology, there is often cross talk between pathways targeted by the SOs. For example, components of the NF-κB pathway and STAT3 can physically interact, cooperate at enhancer or other promoter elements, and negatively regulate each other (Grivennikov and Karin, 2010; He and Karin, 2011). Mutations in Nrf2 can activate the mTOR pathway and induce phosphorylation of S6 by up-regulating Ras small GTPase D, a new activator of the mTOR pathway (Sheng and Sun, 2011). After treatment with 0.6 to 75 mg/m² per hour for 5 days, differentiation of immature blasts increased in four of nine patients, as measured by increased expression of CD11b and CD14 and reduced expression of CD33 and CD34. Increased apoptosis was also detected as a loss of membrane potential in mitochondria in 3 patients. However, the maximum tolerated dose was not reached in this study, and differential counts did not change significantly. CDDO was also tested in a phase I dose-escalation study in patients with advanced solid tumors (http://clinicaltrials.gov/ct2/show/NCT00322140). CDDO was given to seven patients by continuous infusion (0.6–38.4 mg/m² per hour) for 5 days in 28-day cycles to determine the maximum tolerated dose, toxicity, and pharmacokinetics and pharmacodynamics of the drug (Speranza et al., 2012). Plasma concentrations of CDDO above 1 μM, the target blood level determined in preclinical studies, were achieved in only a single patient. No antitumor activity or induction of apoptosis in PBMCs, as determined by poly (ADP-ribose) polymerase cleavage, was observed. This study was terminated because of adverse thrombotic events in four patients, although it was not possi-
ble to determine whether these adverse events were the result of CDDO or the well established high rate of thromboembolism in patients with metastatic disease.

Because of the lower potency of CDDO and the need to administer it intravenously, development efforts were switched to CDDO-Me, which is orally active and more potent. Interim results from dose-escalation studies with bardoxolone methyl (http://clinicaltrials.gov/ct2/show/NCT00508807) in 34 or 47 patients with advanced, refractory solid tumors or lymphoid malignancies have been presented (Dezube et al., 2007; Hong et al., 2008). The drug was administered orally for 21 of every 28 days at doses from 5 to 1300 mg/day. Modulation of the SO targets Nrf2, STAT3, and NFκB activity was confirmed in both studies. Bardoxolone methyl was well tolerated; 91% of patients had minimal toxicities (< grade 2) even when administered for up to 1 year, and a dose of 900 mg/day was set for phase 2 studies. Of 30 assessable patients in the second study, 40% achieved disease stabilization and two objective responses were seen (Hong et al., 2008). The results of this phase 1 study have been published (Hong et al., 2012).

In the phase 1 trials involving 81 patients with cancer, bardoxolone methyl unexpectedly reduced serum creatinine levels and increased the baseline estimated glomerular filtration rate (eGFR). To confirm these results, 20 patients with moderate to severe chronic kidney disease (CKD) and type 2 diabetes were treated with the drug (Pergola et al., 2011a). Patients received 25 mg of bardoxolone methyl for 28 days and then 75 mg of drug for another 28 days. Baseline eGFR increased an average of 7.2 ml/min per 1.73 m²; creatinine clearance increased whereas serum creatinine, blood urea nitrogen, and levels of circulating endothelial cells all declined. It is noteworthy that these significant improvements in kidney function were observed throughout the study in almost 90% of the patients, without any serious drug-related adverse events in this open-label, phase 2a study. In a subsequent phase 2, placebo-controlled, double-blind, randomized trial, 227 patients with stage 3 or 4 CKD were treated with 25, 75, or 150 mg of bardoxolone methyl (Pergola et al., 2011b). The primary objective in this BEAM trial (Bardoxolone Methyl Treatment: Renal Function in CKD/Type 2 Diabetes, NCT00811889)
was a change in eGFR. This marker of kidney function increased within 4 weeks of treatment with bardoxolone methyl, peaked at 12 weeks, and was stable through 52 weeks. The primary outcome was achieved at 24 weeks, with a significant improvement from the baseline eGFR in all groups treated with bardoxolone methyl compared with the placebo group (mean differences of 8.2 ± 1.5, 11.4 ± 1.5, and 10.4 ± 1.5 ml/min per 1.73 m² in the 25-, 75-, and 150-mg groups, respectively), and these significant changes were still maintained at 52 weeks. These changes in eGFR were accompanied by significant changes in blood chemistry, including declines in blood urea nitrogen, serum phosphorus, uric acid, and magnesium. Although the number of adverse events was more common in patients treated with bardoxolone methyl than in the placebo group, muscle spasms were the most common adverse event and frequently disappeared, whereas other adverse events were generally mild to moderate. Despite the potential utility of bardoxolone methyl for increasing kidney function in CKD, a disease for which there is no effective treatment, eGFR is only a surrogate marker for actual GFR and kidney function. Moreover, the confirmation of a long-term clinical benefit after these reported improvements is needed and will be evaluated in the BEACON study (Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes; http://clinicaltrials.gov/ct2/show/NCT01351675). This ongoing worldwide phase 3 study will evaluate the ability of bardoxolone methyl to slow the progression of end-stage renal disease or lessen cardiovascular death in approximately 1600 patients with stage 4 CKD and advanced type 2 diabetes.

In the clinical trials thus far with bardoxolone methyl, safety issues have been minimal (Pergola et al., 2011b). Likewise, many other SOs have been fed safely to both rats and mice for prolonged periods of time, sometimes for up to a year, with few untoward effects. Most of the data from animal toxicology studies remain unpublished, proprietary information. However, it is clear from the decision of the FDA to allow long-term clinical administration of bardoxolone methyl in a phase 3 trial that this agent seems to have a good safety profile.

VIII. Summary and Future Perspectives

The ultimate utility of SOs for prevention of disease rests on their ability to facilitate homeostatic responses to stress. Although their enhancement of Nrf2 activity is a critical aspect of such homeostasis, SOs have many other important molecular targets, which are connected through complex networks of feedback responses. In this article, we have reviewed additional interactions of SOs with regulatory networks such as NF-κB, PPAR-γ, JAK-STAT, HER2/ErbB2/neu, PTEN, PI3K/Akt, mTOR, TGF-β, and the thiold proteome, all of which are involved in response to stress. The concerted, integrated action of these various networks is ultimately what provides homeostasis and allows the development of pharmacologically useful drugs. Particularly because it is now realized from genetic studies that single-targeted enhancement of Nrf2 (as results from mutations of either Keap1 or Nrf2) can have undesirable cancer-enhancing activity (Kensler and Wakabayashi, 2010), it becomes all the more important to emphasize that SOs are not single-target drugs. Rather, they can interact with a wide range of molecular targets, and such interactions have desirable effects, including prevention of cancer, and many other diseases, in many different organs. However, SOs are not “magic bullets” for cures, and to be used most effectively, they should be used as early as possible in the pathogenesis of any disease, when a homeostatic agent is appropriate. Attempts to use SOs for treatment of end-stage inflammatory disease, when irreversible cell death and tissue damage have occurred, will most likely end in failure.

SOs are thus in the vanguard of development of new drugs designed to interact with entire networks (Barabási et al., 2011; Vidal et al., 2011) in the new science of “network pharmacology,” or “polypharmacology” (Hopkins, 2007, 2008). Ultimately, as noted by Barabási (2007), . . . the fundamental question of where function lies within a cell is slowly shifting from a single-minded focus on genes to the understanding that behind each cellular function there is a discernible network module consisting of genes, transcription factors, RNAs, enzymes, and metabolites. This understanding forces us to view diseases as the breakdown of selected functional modules, rather than as single or small groups of genes.

There is thus a need to synthesize “a new generation of drugs that perturb biological networks rather than individual targets” (Hopkins, 2008). The appropriate use of multifunctional drugs, such as SOs, will depend on understanding the biological context in which they are to be used and, just as importantly, their appropriate dosages. It may be desirable to use a specific SO at a given dose level early in pathogenesis, but higher doses can provide opposite results and may not be appropriate for treatment of advanced inflammatory disease. However, the induction of apoptosis by high doses of SOs may be useful for treatment of invasive cancer, especially if the SOs are combined with chemotherapeutic or immunomodulatory drugs.

To account for this multifunctionality and contextuality of SOs, one need look only at the evolution of these molecules as drugs. To begin with, pentacyclic OA appeared in the evolution of plants as a consequence of a unique folding of the linear squalene molecule, driven by a stereospecific oxidosqualene cyclase. The stereochemistry of the five rings and the eight exocyclic carbons of OA provide specific recognition of protein motifs in cells. At the same time, this specific stereochemistry, especially that of the exocyclic carbon atoms, prevents ran-
dom contact of OA with all cellular proteins (Sporn et al., 2007). Plants containing OA have been ingested by animals for millennia without harmful effects and with some benefit undoubtedly resulting from the weak anti-inflammatory effect of OA. Thus, evolution has provided its own selective “wisdom” for the eventual design of SOs. The skill of the synthetic organic chemist has now been added to this evolutionary wisdom, to maximize the selective, contextual interactions of OA with target proteins by inserting new enone functions and electron-withdrawing substituents, such as –CN, to enhance Michael reactivity and create molecules thousands of times more active than OA itself but still relatively nontoxic. We have described some of these useful actions here. This paradigm of using synthetic organic chemistry to enhance pharmacological utility of a natural product now awaits further development with other stereochemically unique triterpenoid scaffolds, and it can again be predicted that multifunctional drugs will be the result.

Beyond the synthetic chemistry, the biological evaluation of the utility of such multifunctional drugs will need to be done in the context of their role in modulating the overall physiological behavior of complex, interactive cellular networks (Levy et al., 2010). This will require not only cell-based assays but also eventual validation in vivo. The ability of SOs to control both the inflammatory and the oxidative stress that drives so many human diseases is central to their potential clinical usefulness. We hope that synthetic triterpenoids will have a useful future in preventing or alleviating the pain and suffering caused by many chronic diseases. As summarized here, SOs should provide a useful model to assist in reaching that goal.

Acknowledgments
This work was supported by National Institutes of Health National Cancer Institute [Grant R01-CA78814]; the National Foundation for Cancer Research; the Breast Cancer Research Foundation; and Reata Pharmaceuticals. Many colleagues have contributed greatly to this work over the past 15 years. Special thanks are due to the following: for chemistry, G. Gribble, T. Honda, H. Finlay, L. Bore, B. Rounds, F. Favaloro, T. Janosik, J. Han, H. Yoshizawa, C. Sundrarajan, E. David, M. Lajoie, E. Pedagamas, J. Xiang, E. Anderson and M. Visnick. For biology, N. Suh, Y. Wang, A. Place, M. Rendi, E. Heiss, K. Mix, M. Yore, I. Pitha-Rowe, E. Kim, K. Tran, C. Williams, R. Risingsong, D. Royce, P. Talalay, A. Dinkova-Kostova, T. Kessler, M. Yates, S. Biswal, R. Thimmulappa, J. Letterio, J. Handa, E. Duh, F. Beal, A. Albini, M. Konopleva, M. Andreeff, J. Reed, C. Meyer, C. Wigley, D. Ferguson, S. Ruiz, and I. Dulubova. Special appreciation is owed to C. Nathan and the late A. Roberts for their inspiration and assistance in starting this project and to G. Gribble and T. Honda for their leadership with the synthetic chemistry. G. Tuson has provided helpful assistance with the manuscript and figures.

Authorship Contributions
Wrote or contributed to the writing of the manuscript: Liby and Sporn.

References
CDDO and its derivatives.

References


Authorship Contributions
Wrote or contributed to the writing of the manuscript: Liby and Sporn.

Acknowledgments
This work was supported by National Institutes of Health National Cancer Institute [Grant R01-CA78814]; the National Foundation for Cancer Research; the Breast Cancer Research Foundation; and Reata Pharmaceuticals. Many colleagues have contributed greatly to this work over the past 15 years. Special thanks are due to the following: for chemistry, G. Gribble, T. Honda, H. Finlay, L. Bore, B. Rounds, F. Favaloro, T. Janosik, J. Han, H. Yoshizawa, C. Sundrarajan, E. David, M. Lajoie, E. Pedagamas, J. Xiang, E. Anderson and M. Visnick. For biology, N. Suh, Y. Wang, A. Place, M. Rendi, E. Heiss, K. Mix, M. Yore, I. Pitha-Rowe, E. Kim, K. Tran, C. Williams, R. Risingsong, D. Royce, P. Talalay, A. Dinkova-Kostova, T. Kessler, M. Yates, S. Biswal, R. Thimmulappa, J. Letterio, J. Handa, E. Duh, F. Beal, A. Albini, M. Konopleva, M. Andreeff, J. Reed, C. Meyer, C. Wigley, D. Ferguson, S. Ruiz, and I. Dulubova. Special appreciation is owed to C. Nathan and the late A. Roberts for their inspiration and assistance in starting this project and to G. Gribble and T. Honda for their leadership with the synthetic chemistry. G. Tuson has provided helpful assistance with the manuscript and figures.


AD

LIBY AND SPORN


TRITERPENOIDS FOR DISEASE PREVENTION AND TREATMENT


